

Stroke rehabilitation

Cost-utility analysis: intensity of physiotherapy rehabilitation

NICE guideline GID-NG10175

Economic analysis report

April 2023

Draft for Consultation

*This analysis was developed by the
Guideline Development Team at NICE*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2023. All rights reserved. Subject to Notice of rights.

Contents

1	Introduction	7
2	Methods	8
2.1	Model overview	8
2.1.1	Comparators	8
2.1.2	Population.....	8
2.2	Approach to modelling.....	8
2.2.1	Model structure	9
2.2.2	Uncertainty.....	9
2.3	Model inputs.....	11
2.3.1	Summary table of model inputs.....	11
2.3.2	Initial cohort settings	14
2.3.3	Life expectancy.....	15
2.3.4	Health-related quality of life (utilities).....	15
2.3.5	Resource use and costs.....	31
2.4	Computations	37
2.5	Sensitivity analyses	38
2.5.1	Cohort settings.....	38
2.5.2	Mortality	39
2.5.3	Clinical studies used to inform treatment effect	39
2.5.4	Post-intervention treatment effect and extrapolation	41
2.5.5	Rehabilitation costs.....	42
2.5.6	Ongoing costs.....	43
2.5.7	Length of stay reduction.....	43
2.6	Model validation	44
2.7	Estimation of cost effectiveness	44
2.8	Interpreting results.....	44
3	Results	45
3.1	Base case	45
3.1.1	Differences between deterministic and probabilistic results.....	49

3.2	Sensitivity analyses	49
4	Discussion	55
4.1	Summary of results	55
4.2	Limitations and interpretation.....	55
4.3	Generalisability to other populations or settings	58
4.4	Comparisons with published studies.....	58
4.5	Conclusions.....	59
4.6	Implications for future research	59
	Appendices.....	66
	Appendix A: Search strategy	66
	A.1 Health Economics literature search strategy.....	66
	Appendix B: Clinical outcomes by study	75
	Appendix C: Meta-analysis of EQ-5D-3L.....	81

1 Introduction

2 There are 100,000 new strokes per year.⁵⁸ Stroke can have a significant effect on both
3 physical function and quality of life^{1, 38} for individuals and also their carers.²⁹ Stroke
4 rehabilitation aims to help people regain function and improve quality of life. Many people,
5 however, still need home adaptations and home or residential care which results in high
6 costs that fall on both the NHS and social services and the individual (due to means testing
7 of home and residential care).

8 The 2013 CG162 guideline recommended offering patients “initially at least 45 minutes of
9 each relevant stroke rehabilitation therapy for a minimum of 5 days per week to people who
10 have the ability to participate, and where functional goals can be achieved.” In this 2023
11 update, the committee reviewed additional evidence about intensity of rehabilitation and
12 concluded that the clinical evidence supported increasing the recommended physiotherapy
13 time to 1-2 hours, for those able to participate.

14 Exploring the cost-effectiveness of increased physiotherapy time was prioritised for new
15 economic modelling as this would be a change in practice that is likely to result in a
16 substantial resource impact to the NHS in terms of additional physiotherapy time. Some
17 published economic studies were identified in this area based on individual clinical studies,
18 but it was agreed that an analysis incorporating as much of the clinical evidence base as
19 possible should be undertaken where uncertainties can be explored to help inform committee
20 decision making.

21

2 Methods

2.1 Model overview

3 A cost-utility analysis was undertaken where lifetime quality-adjusted life years (QALYs) and
4 costs from a current UK NHS and personal social services perspective were considered. The
5 analysis followed the standard assumptions of the NICE reference case for interventions with
6 health outcomes in an NHS setting including discounting at 3.5% for costs and health
7 effects.⁴¹ An incremental analysis was undertaken.

8 2.1.1 Comparators

9 The existing recommendation for rehabilitation is at least 45 minutes, 5 days a week of each
10 therapy. This analysis aims to explore whether higher intensity physiotherapy is cost
11 effective.

12 The following comparators were included in the analysis:

- 13 1. Less intensive physiotherapy: >45 mins – 1 hour physiotherapy, 5 days a week
- 14 2. More intensive physiotherapy: 1 to 2 hours of physiotherapy, 5 days a week

15 The choice of intensity comparator was based on the availability of clinical evidence. The
16 committee considered the systematic review of the clinical evidence and agreed it provided
17 evidence that more intensive physiotherapy than is currently recommended could provide
18 additional clinical benefit. Most of this evidence related to 1 to 2 hours of physiotherapy.
19 Evidence was limited for other therapies. In addition, to be able to undertake cost
20 effectiveness analysis evidence on quality of life as measured by a utility score was required.
21 A summary of available data is included in Appendix B: of this report and in Evidence Review
22 E - Intensity of rehabilitation, which contains the full details.

23 The committee decided to conduct a broad and comprehensive review of the clinical
24 evidence to understand the impact of higher intensity rehabilitation. As a result, the types of
25 studies included are heterogenous and there was overlap with reviews of specific
26 interventions.

27 This economic analysis aims to take a similarly broad approach, utilising the evidence from
28 the clinical review to inform whether or not higher intensity physiotherapy rehabilitation may
29 be cost effective for the NHS. This necessarily required pooling of quite different studies.

30 2.1.2 Population

31 The population of the analysis was adults who have had a stroke and require physiotherapy
32 as part of their rehabilitation, and who can tolerate more than 45 minutes of therapy in a day.

2.2 Approach to modelling

34 Incremental lifetime costs and QALYs per person for more intensive physiotherapy compared
35 to less intensive physiotherapy were calculated based on data from randomised controlled
36 studies identified by the systematic review of the clinical evidence. Studies were included in
37 the model if they reported:

- 1 • EQ-5D-3L quality of life data or
- 2 • measures that could be mapped to EQ-5D-3L.

3 **2.2.1 Model structure**

4 A systematic review of the literature was undertaken to identify existing health economic
5 analyses of higher intensity rehabilitation for people following a stroke. This review is
6 summarised in Evidence Review E - Intensity of rehabilitation. Existing models were
7 considered to identify possibly relevant and appropriate model structures.

8 The structure used was an adaptation of the model developed as part of the 2013 CG162
9 guideline⁴⁰ that compared more versus less intensive therapy delivered by a multidisciplinary
10 team. A life table approach was taken to the analysis. Life tables for England⁵⁰ were adjusted
11 for the increased mortality in people who have had a stroke. This estimated the number of
12 people alive after each 1-week period (each cycle) and this was used to estimate life years
13 for people in the model. It was assumed that mortality is not impacted by the type of
14 rehabilitation received and so life expectancy did not vary by comparator. A 1-week cycle
15 length was used to allow physiotherapy rehabilitation costs and treatment effects to be
16 applied by week.


17 Quality of life (utility) values were attributed to people who were alive in the model that
18 depended on the rehabilitation received ('more intensive physiotherapy' or 'less intensive
19 physiotherapy'). This resulted in differences in QALYs between patients.

20 Differences in total costs between the groups were due to differences in the cost of delivering
21 physiotherapy. Differences in care costs post-rehabilitation related to differences in outcomes
22 were also modelled. A length of stay saving with more intensive physiotherapy was also
23 applied in a sensitivity analysis.

24 **2.2.2 Uncertainty**

25 The model was built probabilistically to take account of the uncertainty around input
26 parameter point estimates. A probability distribution was defined for each model input
27 parameter. When the model was run, a value for each input was randomly selected
28 simultaneously from its respective probability distribution; mean costs and mean QALYs
29 were calculated using these values. The model was run repeatedly – 1,500 times for each
30 analysis – and results were summarised.

31 When running the probabilistic analysis, multiple runs are required to account for random
32 variation in sampling. To ensure the number of model runs were sufficient in the probabilistic
33 analysis convergence was checked for incremental costs, incremental QALYs and
34 incremental net monetary benefit at a threshold of £20,000 per QALY gained. This was done
35 by plotting the number of runs against the mean outcome at that point (see example in
36 Figure 1) for the base-case analysis. Convergence was assessed visually, and all had
37 stabilised before 1500 runs.

Figure 1: Checking for convergence of incremental QALYs (lifetime analysis for Scenario 1a)

Scenario 1a: weekly reduction of EQ-5D mean difference until no difference between was seen between higher and lower intensity groups, meaning higher intensity leads to faster stroke recovery.
Abbreviations: QALYs=quality-adjusted life-years.

1 The way in which distributions are defined reflects the nature of the data, so for example cost
2 were given a gamma distribution, which is bounded by 0, reflecting that costs cannot be less
3 than 0. In the distributions are described in Table 1 and the specific distribution parameters
4 are listed in Table 2 in the next section. Probability distributions in the analysis were
5 parameterised using error estimates from data sources where possible.

6 **Table 1: Description of the type and properties of distributions used in the**
7 **probabilistic sensitivity analysis**

Parameter	Type of distribution	Properties of distribution
SMRs	Lognormal	<p>The natural log of the mean and standard error were calculated as follows:</p> <ul style="list-style-type: none"> • Mean = $\ln(\text{mean cost}) - SE^2/2$ • SE = $[\ln(\text{upper 95\% CI}) - \ln(\text{lower 95\% CI})]/(1.96 \times 2)$ $\sqrt{\ln \frac{SE^2 + \text{mean}^2}{\text{mean}^2}}$ <p>This formula includes a correction to ensure the mean generated in the probabilistic analysis will be the same as the reported mean.⁵</p>
Baseline EQ-5D % intervention time as inpatient % change in EQ-5D post-intervention	Beta	<p>Bounded between 0 and 1. Derived from mean and its standard error, using the method of moments. Alpha and Beta values were calculated as follows: Alpha = $\text{mean}^2 \times [(1 - \text{mean}) / SE^2] - \text{mean}$ Beta = $\text{alpha} \times [(1 - \text{mean}) / \text{mean}]$</p>

Parameter	Type of distribution	Properties of distribution
		Used for post-intervention EQ-5D change in order to constrain change to a reduction.
Costs Barthel Index scores Post-intervention EQ-5D change	Gamma	Bounded at 0, positively skewed. Derived from mean and its standard error. Alpha and beta values were calculated as follows: <ul style="list-style-type: none"> • Alpha = (mean/SE)² • Beta = SE²/Mean Used for post-intervention EQ-5D change in order to constrain change to a reduction.
Difference in <ul style="list-style-type: none"> • Barthel Index • EQ-5D-3L • Length of stay • Care cost savings per week 	Normal	Unbounded so change may be a decrease or increase. Parameterised by mean and SE.
Regression coefficients for mapping BI to EQ-5D-3L	Normal with Cholesky decomposition	Used to account for covariance between variables as well as variance. Normal distributions parameterised by mean and SE are combined with the variance-covariance matrix.

1 Abbreviations: 95% CI = 95% confidence interval; LOS= length of stay; SE = standard error; SMR = standardised
2 mortality ratio.

3 The following variables were left deterministic (that is, they were not varied in the
4 probabilistic analysis):

- 5 • the cost-effectiveness threshold and discount rate,
6 • general population mortality (based on national data so uncertainty is minimal),
7 • general population EQ-5D-3L by age and sex,
8 • cohort start age and proportion female,
9 • number of days with rehab, additional minutes per day with high intensity physiotherapy,
10 high intensity rehabilitation duration.

11 In addition, various one-way and scenario sensitivity analyses were undertaken to test the
12 robustness of model assumptions. In these, one or more inputs were changed, and the
13 analysis rerun to evaluate the impact on results and whether conclusions on which
14 intervention should be recommended would change. Details of the one-way and scenario
15 sensitivity analyses undertaken can be found in methods section 2.5 Sensitivity analyses.

2.3 Model inputs

17 2.3.1 Summary table of model inputs

18 Model inputs were based on clinical evidence identified in the systematic review undertaken
19 for the guideline, supplemented by additional data sources as required. Model inputs were
20 validated with clinical members of the guideline committee.

21
22 There were four base case (primary) scenarios:

- 1 • Scenario 1 (weekly reduction of EQ-5D mean difference until no difference between
2 was seen between higher and lower intensity groups, meaning higher intensity leads
3 to faster stroke recovery),
4 ○ a) intervention costs only
5 ○ b) with post-rehabilitation care cost savings
6 • Scenario 2 (3-month weekly reduction applied before the difference was maintained,
7 meaning higher intensity leads to permanent health gains).
8 ○ a) intervention costs only
9 ○ b) with post-rehabilitation care cost savings

10 A summary of the model inputs used in the base-case analyses is provided in Table 2 below.
11 More details about sources, calculations and rationale for selection can be found in the
12 sections following this summary table.

13 **Table 2: Overview of parameters and parameter distributions used in the model base-**
14 **case analysis**

Input	Data	Source	Probability distribution
Comparators	1. >45mins - 1hr physiotherapy, 5 days per week 2. 1-2hrs physiotherapy, 5 days per week	Clinical review of 3.1 intensity review	n/a
Population	People who have had a stroke and require physiotherapy, and able to tolerate higher intensity of therapy	Committee consensus	n/a
Cost perspective	UK NHS & personal social services	NICE reference case ⁴⁴	n/a
Time horizon	Lifetime	NICE reference case ⁴⁴	n/a
Discount rate	Costs: 3.5% Outcomes: 3.5%	NICE reference case ⁴⁴	n/a
Cycle length	1 week	Committee consensus	n/a
Cohort settings			
Age	Female: 75 years Male: 71 years	National stroke audit data ⁵⁷	Fixed
% female	48%		
Mortality			
General population mortality	Age and sex dependent	National lifetables 2017-2019 ⁵⁰	Fixed
Stroke standardised mortality ratio	Female: 2.85 (95% CI: 2.66 to 3.05) Male: 2.58 (95% CI: 2.43 to 2.75)	Brønnum-Hansen 2001 ⁷	Lognormal •Log mean (female/male): 1.05/0.95 •Log scale SE (female/male): 0.035/0.032

Input	Data	Source	Probability distribution
Health-related quality of life (utilities)			
General population utilities (used for age-adjustment of stroke-related utilities)	Age and sex dependent	NICE Decision Support Unit ²⁶	Fixed
Baseline utility	0.293	Pooled studies from systematic review for guideline update (EQ-5D-3L – direct or mapped from 5L or BI)	<ul style="list-style-type: none"> •BI studies: gamma (then mapped to EQ-5D-3L) •EQ-5D-5L studies: Beta (first mapped to 3L) See Appendix C: for details
Change from baseline with lower intensity physiotherapy	0.120		Normal (probabilistic change from baseline values were pooled).
Difference in change from baseline with higher intensity physiotherapy	0.050		See Appendix C: for details
Change per week in mean difference post-intervention	-0.0015	Rodgers 2019 ⁵⁵	Gamma (applied to absolute number) <ul style="list-style-type: none"> •SE: 0.001 •Alpha: 1.417 •Beta: 0.001
Higher intensity physiotherapy resource use			
Days of therapy per week	5	As specified for intervention	Fixed
Additional minutes per day with higher intensity	45 minutes	Weighted average from clinical studies used to inform treatment effect	Fixed
Duration of intensity rehabilitation intervention	6 weeks		Fixed
% of inpatient rehabilitation	42%	Inpatient SSNAP 2021 ⁵⁷ as % of total	Beta <ul style="list-style-type: none"> •SE: 0.001 •Alpha: 81009.6 •Beta: 113413.5
Average number of staff required	Inpatient: 2 Post-discharge: 1.3	Committee expert opinion	Fixed
% Rehabilitation assistant	Inpatient: 25% Post-discharge: 25%	Committee expert opinion	Fixed
Barthel index			
Mean difference in BI (0-100) change from baseline at end of intervention with Higher versus lower intensity	4.856	Pooled studies from systematic review for guideline update	Normal (probabilistic change from baseline values were pooled) See Appendix C: for details
Unit costs			
Physiotherapist (hospital/community)	£67/73	PSSRU 2021 ³²	Gamma <ul style="list-style-type: none"> •SE (£67/£73): 13.40/14.60 •Alpha (£67/£73): 25.00 •Beta (£67/£73): 2.68/2.92

Input	Data	Source	Probability distribution
Rehab assistant (hospital/community)	£43/44	PSSRU 2021 ³²	Gamma •SE (£43/£44): 8.60/8.80 •Alpha (£43/£44): 25.00 •Beta (£43/£44): 1.72/1.76
Care cost savings per week, per BI (0-100) point change	£46.79	O'Conner 2011 ⁴⁹	Normal for total weekly cost savings and BI change •Weekly savings (mean (SE)): £1,591 (462.58) •BI point change (mean (SE)): 34 (9.89)
% care costs paid by NHS/PSS	50%	Assumption	Fixed

1 Abbreviations: BI = Barthel Index; NHS and PSS = National Health Service and personal social services; PSSRU
2 = Personal Social Services Research Unit; SE= standard error; SMR = standardized mortality ratio; SSNAP
3 Sentinel Stroke National Audit Programme.

4 2.3.2 Initial cohort settings

5 The population entering the model was assigned a start age of 75 years for women and 71
6 years for men, and 48% women, based on real world data from the national stroke audit in
7 people that received physiotherapy. The data used is shown in Table 3. This was from an
8 extract from SSNAP from April 2016 to March 2021 (SSNAP 2023 – reference forthcoming).
9 Data was only available by age band and so mean ages were estimated assuming the mean
10 age for each age band was the mid-point of the band, and 37 and 82 for the top and bottom
11 groups respectively.

12 **Table 3: Age and sex distribution of patients in the SSNAP dataset who received**
13 **physiotherapy rehabilitation^(a) in England, April 2016 - March 2021**

Age group	Female		Male	
	N	%	N	%
<40	2271	1.42%	2735	1.58%
40-44	1580	0.99%	2550	1.47%
45-49	2897	1.81%	5102	2.94%
50-54	4515	2.83%	8875	5.12%
55-59	5877	3.68%	12462	7.19%
60-64	7971	4.99%	15602	9.00%
65-69	11205	7.02%	18692	10.78%
70-74	17508	10.97%	24323	14.03%
75-79	23188	14.52%	26098	15.05%
>80	82641	51.76%	56966	32.85%
Estimated mean age^(b)	75		71	
% female/male	48%		52%	

14 (a) Receipt of physiotherapy is defined as >0 minutes of physiotherapy rehabilitation assessment + treatment
15 recorded in the dataset.

16 (b) The mean age was estimated using the age group distribution and assuming the mean age for each age
17 band was the mid-point of the band, and 37 and 82 for the top and bottom groups respectively.

1 The mean age in the clinical studies used to inform treatment effects in this analysis ranged
2 from 50 to 75 years with an average of 62 years. The proportion female ranged from 22% to
3 50% with an average of 42%. Real-world data was used for the initial cohort settings so that
4 estimated QALY gains reflected expected real-world benefits in analyses where treatment
5 benefits were extrapolated to a lifetime perspective (how treatment effects are applied in the
6 model is described in Section 2.3.4.2). A sensitivity analysis was done using the average age
7 and proportion female from the clinical trials used to inform treatment effects (see Section 2.5
8 Sensitivity analyses).

9 **2.3.3 Life expectancy**

10 Sex- and age-specific mortality was incorporated into the model using life-tables for England
11 adjusted to reflect the increased mortality rates in people who have had a stroke. It was
12 assumed that mortality does not differ between more intensive and less intensive
13 rehabilitation.

14 2017-2019 lifetables were used.⁵⁰ Note that later data were not used as mortality was much
15 higher during the COVID-19 pandemic. Standardised mortality ratios (SMRs) for all-cause
16 mortality after stroke compared with age/sex-adjusted rates for the general population
17 reported by Bronnum-Hansen et al. 2001⁷ were used. These were from a large Danish study
18 of people who had a stroke 1982-1991 (n=4162) with up to 15 years follow-up. For females
19 this was 2.85 (CI: 2.66, 3.05) over the course of the study and for males 2.58 (CI: 2.43, 2.75).
20 This data was used in the modelling for CG162 and has also been used in a recently
21 published cost-effectiveness analysis relating to stroke rehabilitation.³⁵ More contemporary
22 UK data was not identified. Sensitivity analysis was done with lower SMRs to reflect that
23 outcomes after stroke may have improved over time (see Section 2.5 Sensitivity analyses).

24 The SMRs were included in the probabilistic analysis using a lognormal distribution which
25 was parameterised using the confidence intervals. General population mortality was not
26 varied probabilistically.

27 **2.3.4 Health-related quality of life (utilities)**

28 The aim of more intensive physiotherapy after stroke is to improve functional outcomes and
29 independence so ultimately quality of life. In economic evaluation, a particular measure of
30 health-related quality of life is required known as a utility to calculate QALYs. The NICE
31 reference case specifies that EQ-5D-3L is the preferred measure of utility in adults.

32 Relative treatment effects of more intensive compared to less intensive physiotherapy
33 rehabilitation were based on the systematic review of the clinical evidence undertaken for
34 this guideline update. For full details see Evidence Review E - Intensity of rehabilitation A
35 introduction and quantitative.

36 Limited EQ-5D data was reported in the included clinical studies and so clinical outcomes
37 were mapped to EQ-5D to maximise the data that could be incorporated into the cost
38 effectiveness analysis.

39 The analysis is therefore based on studies from the clinical review that reported EQ-5D utility
40 data, or a clinical outcome that could be mapped to EQ-5D. Methods are described in detail
41 in the following sections.

1 2.3.4.1 Mapping data to EQ-5D-3L

2.3.4.121 Mapping from EQ-5D-5L

3 Of the studies that reported EQ-5D the data available was for the 5L version. This was
4 mapped to EQ-5D-3L using the mapping function developed by the NICE Decision Support
5 Unit using the 'EEPRU dataset'.²⁷ This is the mapping algorithm recommended for use in
6 NICE analyses.

7 The Excel function for mapping study means was used.⁴⁸ Gender is a dichotomous input in
8 this and so EQ-5D values were calculated for men and women separately (applying the
9 overall study mean EQ-5D and age as gender specific values were not available) and
10 calculating an overall study estimate as a weighted average of these estimates using the
11 gender split in the study.

12 Uncertainty in the underlying EQ-5D-5L data was captured in the probabilistic analysis. Total
13 EQ-5D-5L scores are needed for mapping at each time point. The EQ-5D-5L total score and
14 confidence interval at baseline and each follow-up point were mapped to EQ-5D-3L (note
15 that no change from baseline analyses were available). The standard deviation of the
16 mapped EQ-5D-3L was calculated from the mapped confidence interval. The EQ-5D-3L
17 change from baseline and SD at each time point were calculated; change from baseline SDs
18 were estimated assuming a correlation coefficient of 0.5 as recommended in the NICE
19 Guidelines Technical Support Unit (TSU) Guideline Methodology Document 2.¹⁶ Baseline
20 EQ-5D-3L was incorporated in the probabilistic analysis using a beta distribution as this is
21 bounded by 0 and 1 and so reflects the likely range of a utility value (although it is
22 acknowledged that it is possible to get negative utility) and the change from baseline at each
23 time point using a normal distribution. Data was not available to capture uncertainty in the
24 mapping equation.

2.3.4.152 Mapping other clinical outcomes

26 To determine how best to use the available clinical data to estimate QALYs we investigated
27 what outcomes in the clinical review could be mapped to EQ-5D. A quality-of-life search was
28 undertaken looking for studies in a stroke population (for search strategy see Appendix A:

29 We additionally reviewed a published mapping database (Dakin 2020¹⁵) for outcomes used
30 in the intensity clinical review.

31 Table 4 summarises the 6 studies identified that mapped outcome measures reported in the
32 intensity clinical review to EQ-5D. The clinical outcomes were Barthel index (BI), modified
33 Rankin scale (mRS), Hospital Anxiety and Depression Scale (HADS) and the functional
34 independence measure (FIM). All of the studies mapped to EQ-5D-3L and used the UK
35 population tariff. In the clinical review, BI was reported in 18 studies, mRS in 4 studies,
36 HADS in 1 study and FIM in 10 studies.

37 **Table 4: EQ-5D^(a) mapping studies of outcomes in intensity clinical review**

Author, year	Outcome	N ^(b)	Population	Mapping models investigated
Brazier, 2014 ⁶	HADS	286	Depression, anxiety, and phobias	OLS, Tobit, response mapping
Kaambwa 2013 ²	BI	793	Older people	OLS, CLAD and response mapping

Author, year	Outcome	N ^(b)	Population	Mapping models investigated
Peiris, 2020 ⁵¹	FIM	677	Rehabilitation inpatients (e.g. stroke)	OLS; adjusted limited dependent variable mixture models
Rivero-Arias, 2010 ⁵⁴	mRS	2425	Stroke and TIA	OLS, response mapping
van Exel, 2004 ⁶¹	BI	710	Stroke	OLS, response mapping
Whynes, 2013 ⁶³	BI, mRS	1462	Stroke	OLS, response mapping

1 Abbreviations: BI = Barthel Index; CLAD = censored least absolute deviations; EQ-5D = EuroQol 5-dimension;
2 FIM = Functional Independence Measure; HADS = Hospital Anxiety and Depression Scale; mRS = Modified
3 Rankin Scale; OLS = Ordinary least squares; TIA = transient ischemic attack.
4 (a) All studies mapped outcomes to EQ-5D-3L using UK tariff.
5 (b) Responses used in analysis

6 Of the three studies identified that mapped BI only van Excel, 2004 could be used. The
7 models reported in sufficient detail to use for mapping in Kaambwa, 2013 required BI
8 subscores (not just the total score) and so could not be used. Whynes, 2013 mapping
9 models required mRS and BI scores. The mRS mapping required discrete mRS categories to
10 be used and so was not appropriate to use with mean study scores and so could not be
11 used. The committee decided that mapping from HADS should not be used as this is not the
12 primary goal of rehabilitation. The FIM mapping could not be used because it required the
13 four subscale scores, or all the item scores whereas only total scores were available.
14 Therefore, only BI was mapped to EQ-5D-3L for use in the analysis.

2.3.4.153 Mapping Barthel Index (BI) to EQ-5D-3L

16 The Barthel Index consists of 10 items that measure a person's daily functioning particularly
17 activities of daily living and mobility. The total score ranges from 0 (totally dependent) to 20
18 (completely independent). Sometimes the score is expressed on a scale of 0 to 100 by
19 multiplying by 5. It was the top ranked outcome measure for activities of daily living (ADL) by
20 the committee.

21 The committee highlighted the BI's focus on functional mobility and a person's degree of
22 independence and that it may not reflect all aspects of health for someone who has had a
23 stroke (such as cognitive or speech and language abilities). However, it was ultimately
24 deemed appropriate to use for mapping to EQ-5D particularly for interventions that focussed
25 on physical rehabilitation such as physiotherapy as it would allow more evidence to be
26 incorporated into the analysis, albeit evidence that is second best to direct EQ-5D data. This
27 decision was consistent with previous stroke-related economic models which have estimated
28 QALYs using EQ-5D valued mapped from BI scores.³⁰

29 Van Exel 2004⁶¹ was used to map BI to EQ-5D-3L. The van Exel, 2004 mapping equation
30 (using combined 2-month and 6-month data):

- 31 • EQ-5D-3L = -0.25 + 0.05 BI score
- 32 • 95% Confidence intervals: intercept -0.33 to -0.19; slope 0.047 to 0.053

33 The NICE Decision Support Unit (DSU) report on mapping studies states that the clinical and
34 demographic characteristics of people in the estimation sample should be as similar as
35 possible to the characteristics of the 'target' sample to which the mapping algorithm is
36 applied.⁴³ The van Exel analysis was based on a real-world stroke population from the
37 Netherlands (n=598, mean age 73.5y, 54% female). This is similar to the UK stroke

1 population which in the 2020/21 Sentinel Stoke National Audit was 47% female with a
 2 median age of 76 years.⁵⁷ It is slightly older than the average of the studies included in the
 3 intensity review which was mean age 64 years and 42% female. The mean age in the
 4 studies mapped for this analysis ranged from 52 to 76 years.

5 BI and EQ-5D data used in van Exel 2004 were assessed through patient interviews 2 and 6
 6 months after stroke. The analysis employed ordinary least-squares (OLS) regression
 7 techniques to derive mapping algorithms using the 2-month data, the 6-month data and the
 8 combined 2- and 6-month data. The coefficients were the same in all analyses with similar
 9 CIs and similar R² values (0.54, 0.59 and 0.57). The model based on the combined data with
 10 the most data points was used for mapping here.

11 The authors reported that observed and predicted mean values by BI category did not differ
 12 significantly except for the independent category but that intraclass correlation was moderate
 13 to low because the predicted values are more clustered around the mean. Adjusted R², AIC
 14 and BIC statistics were not reported. Validation using an external cohort or by splitting the
 15 sample cohort was not undertaken. However, Kaambwa 2013² applied van Exel in an
 16 external cohort (1,189 UK intermediate care patients) and reported correlation 0.461, Root
 17 mean square error 0.327 and mean absolute error 0.242.²

18 Van Exel uses the 0 to 20 BI scale. Where RCTs reported on a scale of 0-100 this was
 19 therefore divided by five to convert to the 0-20 scale used in the algorithm.

20 Uncertainty in the underlying BI data was captured in the probabilistic analysis. Total BI
 21 scores are needed for mapping at each time point. BI was made probabilistic by varying the
 22 baseline BI using a gamma distribution and the change from baseline at each time point
 23 using a normal distribution. At each follow-up point, the probabilistic baseline value and
 24 change from baseline value were summed and then mapped. This ensured where change
 25 from baseline analyses had been undertaken for the study and so SD reflected covariance,
 26 these were utilised and that uncertainty in the mapping equation can also be incorporated
 27 into the analysis. Where change from baseline analysis had not been undertaken within the
 28 studies, SD were estimated assuming covariance of 0.5 as recommended in the NICE
 29 Guidelines Technical Support Unit (TSU) Guideline Methodology Document 2.¹⁶ Uncertainty
 30 in the mapping equation was also incorporated using Cholesky decomposition and the
 31 variance-covariance matrix for the mapping equation. Covariance was not reported in the
 32 published paper and so was calculated from data provided by van Exel and formulae from
 33 Neter et al. 1983.⁴⁶ The resulting variance-covariance matrix is shown in Table 5.

34 **Table 5: van Exel BI to EQ-5D mapping equation variance-covariance matrix**

	Intercept/constant	BI (slope)
Intercept/constant	0.0012755	
BI (slope)	-0.0000368	0.0000023

35 *BI = Barthel index*

36 **2.3.4.1.4 Clinical studies with utility data**

37 12 studies out of the 32 included in the clinical review for the >1 to 2 hours physiotherapy
 38 category had data that could be used to inform QALY estimation for economic evaluation
 39 (that is EQ-5D or BI). These are shown in Table 6. The 7 studies comparing >1 to 2 hours
 40 physiotherapy 5 days a week to >45 minutes to 1 hour, 5 days a week were used in the base
 41 case analysis. A sensitivity analysis was done using all 12 studies (see section 2.5).

1 The study details and outcome available to map to EQ-5D-3L for each study are summarised
2 in Table 7.

3 **Table 6: Breakdown of >1 to 2 hours physiotherapy studies with data for EQ-5D**
4 **estimation by days of therapy and lower intensity comparator**

Intensity	Studies	Sum of N
>1 to 2 hours	12	2031
<5 days		
Vs >45 mins to 1 hour, <5 days	1	109
Cooke 2010		109
5 days		
Vs <= 45 mins, <5 days	1	59
Yoo 2013		59
Vs <= 45 mins, 5 days	1	70
Glasgow Augmented Physiotherapy Study 2004		70
Vs >45 mins to 1 hour, 5 days	8	1731
Cabanas-Valdes 2016		80
Han 2013		21
Jiang 2020		45
Klassen 2020		75
Lee 2012		40
Rodgers 2019		770
Tollar 2021		680
Kim 2016		20
6 days		
Vs >45 mins to 1 hour, 5 days	1	62
Askim 2010		62

5

Table 7: Details of clinical studies included in base-case analysis

Study	<ul style="list-style-type: none"> • N • Mean age • % female 	Setting	Intervention (weeks)	Last follow-up (weeks)	EQ-5D/BI	Area of focus	Time since stroke ^(a)	Stroke severity	Intervention intensity detail	Control arm detail	CEA?
Cabanas-Valdes 2016 ⁹	<ul style="list-style-type: none"> • N=80 • 75 yrs • 50% 	Inpatient rehabilitation (Spain)	5	5	BI	Functional independence; Core stability	Subacute 23.25 (\pm 16.7) days	Moderate (or NIHSS 5-14)	Core stability exercises and usual care	Conventional therapy programme (1 hour)	No
Han 2013 ²⁴	<ul style="list-style-type: none"> • N=21 • 50 yrs • 22% 	Inpatient rehabilitation (China)	6	6	BI	Upper limb	Subacute (>5 weeks ^(b))	Not stated/unclear	Arm training 2 hours per day	Arm training 1 hour per day	No
Jiang 2020 ³¹	<ul style="list-style-type: none"> • N=45 • NR • 36% 	Inpatient rehabilitation (China)	2	4	BI	Upper limb	Subacute (mean: 20 days)	Moderate (or NIHSS 5-14)	Robot-assisted arm therapy (30 minutes twice a day); Spring arm robot used with a virtual reality game interface that matches the motor skills required to complete the exercise (in addition to usual care).	Conventional rehabilitation 30 minutes twice a day	No
Kim 2016 ³³	<ul style="list-style-type: none"> • N=20 • 66 yrs • 41% 	Inpatient rehabilitation (South Korea)	4	4	Modified BI ^(c)	Lower limb	Subacute (30 days)	Not stated/unclear	90-minutes of circuit training classes	Conventional individual physiotherapy for 30 minutes twice a day.	No
Klassen 2020 ³⁴	<ul style="list-style-type: none"> • N=75 • 57 yrs • 40% 	Inpatient rehabilitation (USA)	4	52	EQ-5D-5L	Mixed	Subacute (27 days (SD 10))	Moderate (or NIHSS 5-14)	Different doses of physical therapy (Dose of 104 minutes was incorporated into the model)	Usual care (48 minutes) included physical therapy was inpatient physical therapy that progressed upper and lower limb functional exercises as tolerated.	No

Study	<ul style="list-style-type: none"> • N • Mean age • % female 	Setting	Intervention (weeks)	Last follow-up (weeks)	EQ-5D/BI	Area of focus	Time since stroke ^(a)	Stroke severity	Intervention intensity detail	Control arm detail	CEA?
Lee 2012 ³⁷	<ul style="list-style-type: none"> • N=40 • 54 yrs • 38% 	Unclear setting (South Korea)	4	4	Modified BI ^(c)	Lower limb	Chronic (mean 7.15 months)	Not stated/ unclear	Balance control trainer (additional 20 minutes a day)	Usual care (1 hour per day)	No
Rodgers 2019 ⁵⁵	<ul style="list-style-type: none"> • N=770 • 61 yrs • 39% 	NHS (mostly outpatient) stroke rehab units (UK)	12	24	EQ-5D-5L (BI also collected)	Upper limb	Chronic stroke (43% were 3-12 months)	Moderate (or NIHSS 5-14)	Robot-assisted training or enhanced upper limb therapy (45 minutes, 3 times per week in addition to usual care)	Usual care only (45 minutes)	Fernandez-Garcia, 2021 ²⁰ (CUA)
Tollar 2021 ⁵⁹	<ul style="list-style-type: none"> • N=680 • 67 yrs • 45% 	Outpatient clinics (Hungary)	5	5	BI	Functional independence	Subacute 2.9 weeks (0.75 SD)	Not stated/ unclear	5 times a week twice daily Exergame sessions (2 hours)	Exergame sessions (1 hour)	No

Abbreviations: BI = Barthel index; CEA = cost-effectiveness analysis; CUA = cost-utility analysis (QALYs as outcome measure); EQ-5D-5L – Euroqol 5 dimensions – 5 level version; SD = standard deviation

(a) Subacute stroke = 7 days – 6 months; Chronic stroke >6 months


(b) All stroke patients admitted to the Affiliated Hospital of Qingdao University Medical College between November 2009 and October 2010 were considered for inclusion in the study. Days to randomisation were 38.30-41.40.


(c) BI test items (i.e., eating and grooming) were revised to reflect the Korean culture and lifestyle.

1 **2.3.4.1.5 Data mapped to EQ-5D-3L by study**

2 Outcomes from all available time points reported in the study were mapped to EQ-5D-3L and
 3 are shown in Figure 2. How this data is used in the analysis is described in Section 2.3.4.2.

Figure 2: Data mapped to EQ-5D-3L by study





1

2 2.3.4.2 Treatment effect higher vs lower intensity physiotherapy

3 All studies reported outcomes around the time the intervention ended. A few also reported at
 4 a time point during the intervention or after the end of the intervention. As seen in the CG162
 5 model, the assumption made about long-term effects after rehabilitation has a significant
 6 impact on cost-effectiveness estimates. Although data was limited, the difference between
 7 groups appeared to potentially reduce after the end of the intervention and so treatment
 8 effect at the end of the intervention was pooled and data after the end of the intervention
 9 were used to inform what happens in the model longer term. The available data and how it
 10 was used in the model are described in detail below.

11 2.3.4.2.1 Initial intervention effects

12 All studies measured effects around the end of the study intervention. The mean difference in
 13 change from baseline for higher versus lower intensity treatment at the end of the
 14 intervention was pooled using inverse variance meta-analysis to estimate the treatment
 15 effect (Appendix C:). In line with methods used in the clinical review, a random effect meta-
 16 analysis was used as there was unexplained heterogeneity in the fixed effects meta-analysis.
 17 The resulted in a pooled mean difference in EQ-5D-3L of 0.050. Data showing the results
 18 from the clinical studies are shown in Table 8 and Figure 3. The variation in results is due to
 19 the clinical review including any study that compared more physiotherapy time with less,
 20 which meant that the studies incorporated in this analysis varied in terms of setting, stroke
 21 population, the interventions used and the delivery, frequency and duration of the
 22 intervention (see section 4.2 for details). In probabilistic analysis this pooled mean difference
 23 is recalculated each time using the mean differences from the probabilistic inputs and the
 24 inverse variance weightings calculated below.

25 Intervention duration varied in the studies between 2 and 12 weeks but no clear trend was
 26 seen related to duration in the available data and so all durations were pooled together and
 27 applied at the weighted average intervention duration in the studies which was 6 weeks. The
 28 weighted average was calculated using the weights calculated for the treatment effect for

1 consistency. A linear increase from 0 mean difference at baseline to the mean difference at
2 end of intervention was applied.

3 A weighted average age, baseline EQ-5D-3L and change from baseline in the lower intensity
4 group was also calculated (Appendix C: Baseline EQ-5D-3L and change from baseline for
5 lower intensity physiotherapy (CFBL-L) are applied in the model so total QALYs are
6 estimated for each group but do not affect incremental QALY calculations (and so cost-
7 effectiveness) because mortality does not vary between comparators in the model. Mean age
8 is used when applying utility age adjustments over time in the model (see Section 2.3.4.3).

9 **Table 8: End of intervention pooled EQ-5D-3L treatment effect (Base case analysis)**


	Mean difference in CFBL (H – L)	Mean difference inverse variance weight ^(a)	Intervention duration (weeks)	Mean age	BL	CFBL-L
Cabanas-Valdes 2016	0.132	12.2%	5	76	0.065	0.233
Han 2013	-0.08	4.1%	6	53	0.320	0.335
Jiang 2020	0.032	14.5%	2	64	0.384	0.004
Kim 2016	-0.066	4.0%	4	66	0.366	0.279
Klassen 2020	-0.007	6.6%	4	57	0.484	0.197
Lee 2012	0.039	10.8%	4	54	0.398	0.025
Rodgers 2019	0.029	23.2%	12	61	0.219	0.036
Tollar 2021	0.101	24.6%	5	67	0.311	0.171
Pooled^(b)	0.050	100%	6	63	0.29	0.12

10 Abbreviations: BL = base line EQ-5D-3L; CFBL = change from baseline; EQ-5D-3L = EuroQol 5-dimension – 3
11 level version; H = higher intensity; L = lower intensity.

12 (a) Weights calculated from inverse variance (random effects assumption) of EQ-5D-3L mean difference in
13 CFBL with higher intensity compared to lower intensity physiotherapy.

14 (b) Pooling is based on a weighted average using weights calculated for treatment effect based on inverse
15 variance.

Figure 3: Mean difference in change from baseline EQ-5D-3L with higher intensity versus lower intensity physiotherapy at end of intervention, by study



Note: All data points are at the end of study intervention except for Lee that additionally reported data at a point before end of the intervention.


1 2.3.4.2.2 Longer term intervention effects

2 Three of the studies used to inform the model reported follow-up longer than the intervention
3 duration: Jiang 2020, Klassen 2020, and Rodgers 2019. EQ-5D-3L change from baseline
4 data from these studies is shown in Figure 4 and mean difference in change from baseline is
5 shown in Figure 5.

6 In Jiang 2020 and Rodgers 2019, EQ-5D-3L continues to increase in both the higher and
7 lower intensity groups after the end of the study intervention but the mean difference
8 between groups reduces over time.


9 Klassen 2020 did not find a benefit with higher intensity over lower intensity physiotherapy at
10 the end of the intervention, therefore it could not be used to inform the waning of the
11 treatment effect post-intervention .

Figure 4: Change from baseline EQ-5D-3L in studies with follow-up after the end of the study intervention



Intervention duration: 2 weeks


Intervention duration: 4 weeks




Intervention duration: 12 weeks

1
2

Figure 5: Mean difference in EQ-5D-3L with higher intensity versus lower intensity after end of study intervention, by study




3 Because not all studies had follow-up beyond the intervention, and studies that did had
 4 different timepoints, it was not considered appropriate to simply use the absolute EQ-5D
 5 values. Instead, we examined how EQ-5D changed over time in the studies with data
 6 available by calculating a change per week. Initially mean change per week and associated
 7 SD (assuming linear change and a correlation co-efficient of 0.5) were obtained from each
 8 study. However, when meta-analysed inclusion of Jiang made no difference to the overall
 9 estimated mean difference (Figure 6) and so the Rodgers data alone was used to inform
 10 change per week in the model.

Figure 6: Change per week in mean difference in EQ-5D-3L after end of study intervention

Abbreviations: CI = confidence interval; SD = standard deviation.

- 1 The change per week in the mean difference in EQ-5D was applied in the model for at least
 2 12 weeks after the end of rehabilitation in the model as this was the follow-up period in the
 3 Rodgers study. Beyond this, an extrapolation assumption was applied:
- 4 1. The change per week in mean difference in EQ-5D continued to be applied until there was
 5 no difference between higher and lower intensity. This assumption equates to higher
 6 intensity speeding up rehabilitation but not resulting in lasting differences between the
 7 groups.
 - 8 2. The difference in EQ-5D between higher and lower intensity that remains after 12 weeks
 9 is maintained for the remaining lifetime. This assumption results in lasting differences
 10 between those that receive higher intensity and lower intensity physiotherapy.
- 11 Figure 7 below shows these two assumptions illustratively. In both scenarios the initial
 12 treatment effect is applied at 6 weeks and then the change per week from Rodgers is applied
 13 for 12 additional weeks however after that the two scenarios differ.

Figure 7: Mean difference in utility over time with higher vs lower intensity

Scenario 1: change per week applied until there is no difference between the higher and lower intensity groups. Area under the curve = QALY gain.

Scenario 2: the difference in EQ-5D between higher and lower intensity that remains 12 weeks post rehabilitation is maintained for the remaining lifetime (full lifetime not shown). Area under the curve = QALY gain.

- 14 The committee discussed whether they considered it was more likely that more intense
 15 rehabilitation led to permanent health gains for people that have had a stroke or just sped up
 16 recovery to choose a base case analysis but agreed that they were not able to do this and so
 17 requested both scenarios to be presented as separate base case analyses.

1 The post-rehab change per week was incorporated into the probabilistic analysis using a
2 gamma distribution. This constrains the change in EQ-5D conservatively, so that in every
3 model simulation the between-arm treatment effect is always reduced after the end of
4 rehabilitation or at the extreme maintained.

5 **2.3.4.3 Age adjustment of utilities**

6 In the model utilities were age-adjusted to account for quality-of-life decreasing with age.

7 Age-specific general population EQ-5D-3L utilities were taken from an analysis of direct
8 observations of EQ-5D-3L from the Health Survey for England 2014 as recommended in the
9 2022 report from the NICE Decision Support Unit.⁴⁸ These were then applied multiplicatively
10 to age-standardise the treatment-specific utilities, such that people over the study baseline
11 age of 63 had a lower baseline utility (Table 9). This was applied after the treatment effect,
12 so that the QALYs gained from rehab will gradually reduce over the time horizon.

13 Age-specific utilities were not varied probabilistically.

14

1

2 **Table 9: Utility age multipliers**

age	EQ-5D-3L		Multiplier used	
	Females	Males	Females	Males
50	0.859	0.879	1.058	1.045
51	0.856	0.877	1.054	1.042
52	0.853	0.874	1.050	1.039
53	0.850	0.871	1.046	1.036
54	0.846	0.868	1.042	1.032
55	0.843	0.866	1.038	1.029
56	0.839	0.863	1.033	1.026
57	0.836	0.860	1.029	1.022
58	0.832	0.857	1.024	1.019
59	0.828	0.854	1.020	1.015
60	0.824	0.851	1.015	1.011
61	0.821	0.848	1.010	1.008
62	0.817	0.844	1.005	1.004
63	0.812	0.841	1.000	1.000
64	0.808	0.838	0.995	0.996
65	0.804	0.835	0.990	0.992
66	0.800	0.831	0.984	0.988
67	0.795	0.828	0.979	0.984
68	0.791	0.824	0.973	0.980
69	0.786	0.821	0.967	0.976
70	0.781	0.817	0.962	0.972
71	0.776	0.814	0.956	0.967
72	0.771	0.810	0.950	0.963
73	0.766	0.806	0.943	0.959
74	0.761	0.803	0.937	0.954
75	0.756	0.799	0.931	0.950
76	0.751	0.795	0.924	0.945
77	0.745	0.791	0.917	0.941
78	0.740	0.787	0.911	0.936
79	0.734	0.784	0.904	0.931
80	0.728	0.780	0.897	0.927
81	0.723	0.776	0.890	0.922
82	0.717	0.772	0.882	0.917
83	0.711	0.767	0.875	0.912
84	0.705	0.763	0.867	0.907
85	0.698	0.759	0.860	0.903
86	0.692	0.755	0.852	0.898
87	0.686	0.751	0.844	0.893

88	0.679	0.747	0.836	0.888
89	0.672	0.742	0.828	0.883
90	0.666	0.738	0.819	0.877
91	0.659	0.734	0.811	0.872
92	0.652	0.729	0.802	0.867
93	0.645	0.725	0.794	0.862
94	0.638	0.721	0.785	0.857
95	0.630	0.716	0.776	0.852
96	0.623	0.712	0.767	0.847
97	0.616	0.708	0.758	0.841
98	0.608	0.703	0.749	0.836
99	0.601	0.699	0.740	0.831
100	0.593	0.695	0.730	0.826
101	0.586	0.690	0.721	0.821

1

2 **2.3.4.4 Carer quality of life**

3 The NICE reference case perspective on outcomes states that evaluations should consider
4 all health effects for patients, and, when relevant, carers. Carer health-related quality of life
5 (HRQoL) was identified as an important outcome for this topic and was included in the
6 clinical review protocol, however no evidence was identified. One physio RCT (n=59) that
7 assessed 30 minutes of caregiver-mediated exercise (overseen by a physiotherapist) for 5
8 days a week to compared to usual care found no clinical important difference in carer quality
9 of life <6 months.⁶²

10 We then referred to the Decision Support Unit (DSU) for possible approaches to infer the
11 impact of higher intensity on carer quality of life. The DSU conducted systematic reviews of
12 economic evaluations that incorporated carer HRQoL in technology assessments (TAs)⁵² as
13 well as the general literature.⁵⁶ The results from both reviews concluded that a relationship
14 did exist between HRQoL of carers (with most studies using carer-EQ-5D scores) and
15 interventions that improved outcomes. However, there was a lack of stroke-based studies;
16 only one²¹ was identified in either review, which reported results that did not meet the criteria
17 for the NICE reference case (cost per 1-unit improvement in the General Health
18 Questionnaire-12 (GHQ-12)). Despite this, the reviews did conclude that including carer
19 HRQoL consistently increased incremental QALYs, meaning that study conclusions of cost-
20 effectiveness may be slightly conservative if full QALY gain is not captured.

21 Therefore, the quality-of-life search was also used to investigate whether there were any
22 studies that explored carer quality of life in relation to stroke survivors to support
23 incorporating this into the analysis, as measure by either:

- 24 • EQ-5D or other utility measures (e.g., 36-Item Short Form Survey (SF-36))
- 25 • Clinical outcomes reflecting the disability severity of the stroke survivor (BI, mRS)

26 The evidence identified was mixed: studies that assessed the relationship between carer
27 HRQoL and clinical outcomes for stroke survivors found either no relationship between
28 disability level (BI and mRS) and caregivers (Chen 2010¹², Carod-Artal 2009¹⁰), while those
29 that did find a relationship were not appropriate to use in a sensitivity analysis as they used

1 quality of life measures other than EQ-5D-3L (Persson, 2015⁵³, Ogunlana, 2014{, #4640}).
 2 Several studies reported carer quality of life decrements based on caregiver burden which
 3 could not be incorporated into the analysis. Due to the lack of data suggesting a quantitative
 4 relationship with utility and uncertainty towards the magnitude of effect, it was decided that
 5 carer quality-of-life could not be incorporated in the model.

6 2.3.5 Resource use and costs

7 As mortality does not differ between comparators it was not necessary to incorporate stroke-
 8 related costs that will not vary between people that receive higher and lower intensity
 9 physiotherapy rehabilitation. Therefore, only differences in costs between groups were
 10 included.

11 2.3.5.1 Additional intervention costs

12 Additional intervention costs will relate to the delivery of more physiotherapy time. The
 13 existing recommendation for rehabilitation is at least 45 minutes, 5 days a week. This
 14 analysis is looking at a higher intensity of 1-2 hrs 5 days a week. The additional
 15 physiotherapy time per day was based on the weighted average additional time from the
 16 clinical studies used to inform the treatment effect (see Table 10). This was an additional 45
 17 minutes per day. Rehabilitation duration was based on the weighted average intervention
 18 duration from the clinical studies that informed treatment effect. This was 6 weeks (see Table
 19 8). Note that this is also used as the time point when treatment effect from the trials is
 20 applied.

21 **Table 10: Additional minutes per day with more intensive physiotherapy, by study**

Input	N	Additional minutes per day 5 days a week ^(a)	Delivery
Cabanas-Valdes 2016	79	15	Not specified
Han 2013	20	60	Not specified
Jiang 2020	45	30	Not specified
Kim 2016	20	30	Group therapy ^(c)
Klassen 2020	73	56	Not specified
Lee 2012	40	20	Not specified
Rodgers 2019	675	36 ^(b)	Individual therapy
Tollar 2021	641	60	Group therapy. 2 physiotherapists for 6-8 people
Weighted average		45	

22 (a) Based on actual study mean if reported and planned time if not.

23 (b) Usual care was defined as 5 sessions per week with 3 additional sessions given in the more intensive group
 24 – additional time is therefore the total additional time divided by 5 (in line with approach taken in the clinical
 25 review)

26 (c) The control group received individual physiotherapy while the more intensive group received circuit training
 27 classes where at least two people were under the supervision of one physiotherapist who attended all
 28 classes.

29 While the clinical trials included in the review were in a particular setting, in reality the
 30 rehabilitation pathway spans settings and varies by individual patient and by area.

1 Rehabilitation will start during the acute inpatient stay for stroke. People may then either stay
2 in hospital or be discharged via Early Supported Discharge and receive rehabilitation at
3 home via the early supported discharge team, however the rehabilitation they receive should
4 be the same. Following this people may be discharged from rehabilitation or transferred to a
5 community rehabilitation team. The costs reflect average resource use for the overall
6 population across that pathway that might receive more intensive physiotherapy. In addition
7 to the intensity inputs described above, a number of assumptions were required to estimate
8 costs. The following was assumed for costing purposes:

- 9 • Of the total rehabilitation duration, the proportion of time spent as an inpatient was
10 estimated using overall rehabilitation duration in the model (6 weeks) and assuming
11 2.5 weeks would be as an inpatient (based on the mean inpatient stay from national
12 audit data)⁵⁷
- 13 • The average number of staff required to deliver more intensive physiotherapy would
14 be 2 in hospital and 1.33 post-discharge (assuming two thirds of people have 1:1
15 therapy and 1/3 require 2 people), based on committee expert opinion.
- 16 • Staffing would be 75% physiotherapist time and 25% rehabilitation assistant time,
17 based on committee expert opinion (this was also assumed in the 2013 CG162
18 model)⁴⁰
- 19 • A physiotherapist would typically be band 6 and a rehabilitation assistant band 3.
- 20 • No additional time would be required for documentation, planning and meetings
21 related to the additional rehabilitation (as the number of patients will not increase)
22 based on committee expert opinion.

23 Staff unit costs of £67/73 per hour of patient-related time for a hospital/community
24 physiotherapist respectively and £43/£44 for a hospital/community rehabilitation assistant
25 were applied in the analysis.

26 Physiotherapist unit costs are applied from standard national sources³² that account for the
27 following:

- 28 • Average salary for band
- 29 • Salary oncosts e.g., pension
- 30 • Overheads attribution (management, admin and estates staff; non-staff overheads)
- 31 • Capital cost attribution for a physiotherapist
- 32 • Average actual working hours (taking account of holiday etc)
- 33 • Qualification costs (as reported but with productivity and individual costs excluded in line
34 with an NHS/PSS perspective).
- 35 • Time spent not directly related to patients was also included. This was last reported in the
36 2015 report and was validated with the committee:¹⁴
 - 37 ○ 73% direct patient activity (time spent with patients or on patient-related tasks) and
 - 38 ○ 27% non-direct activities/other as (includes training, supervision and general non-
39 patient related admin)

40 Rehabilitation assistant costs are not specifically reported and so have been calculated using
41 the same methods based on an average band 3 salary for another staff group and not
42 including qualification costs (on the basis that a specific degree qualification is not required).

43 Based on the above data inputs, the average additional cost per week of more intensive
44 physiotherapy was £382.14.

In the probabilistic analysis, the proportion of time spent as an inpatient was parametrised as a beta distribution (so it varied between 0 and 1) using the reported interquartile range for the mean inpatient stay. Unit costs were parametrised as a gamma distribution (so that they were always above zero) assuming a standard error that is 20% of the mean in the absence of uncertainty information. Average staff per session, additional minutes per day and the rehabilitation duration were not varied probabilistically.

2.3.5.2 Hospital length of stay savings

Length of stay savings were not incorporated into the base-case analysis.

The committee highlighted that higher intensity physiotherapy could lead to people meeting functional goals that allow them to be discharged from hospital sooner. Length of stay was not an outcome in the clinical review and so studies in an inpatient setting were checked for this outcome. None of the studies used to inform treatment effect in the model reported length of stay as an outcome.

Three studies in the in the clinical review reported length of stay data.^{18, 23, 28} This is shown in Table 11 and Figure 8.


The control group in each trial had different lengths of stay (English 2015¹⁸ (55 days); Glasgow 2004²³ (54 days) and Howe 2005²⁸ (23.1 days)) and all are longer than the average reported in SSNAP (17.5 days). The committee highlighted that implementation of early supported discharge has meant that length of stay in has reduced and they were concerned whether additional length of stay savings would be achievable. Recommendations for early supported discharge have also been updated in the 2023 guideline, which could lead to changes in the future regarding the length of stay for stroke survivor and thus creating additional uncertainty towards potential length of stay savings. The committee therefore agreed that length of stay savings would not be included in the base-case analysis, although a sensitivity analysis was done including them (see 2.5.7).

Table 11: Length of stay

Study	N	Category in clinical review	Mean Length of stay in hospital		Mean difference
			Lower intensity	Higher intensity	
English 2015 ¹⁸	172 ^(a)	1-2 hours, 5 days a week versus	55 (SD 49.0) days	46 (SD 38.0) days	<ul style="list-style-type: none"> -9.2 days, p=0.23 17% lower
Glasgow Augmented Physiotherapy Study 2004 ²³	70	≤45 minutes, 5 days a week	54 days (range 8-180)	45 days (range 4-123)	<ul style="list-style-type: none"> -9 days, p=0.29 17% lower
Howe 2005 ²⁸	35	1-2 hours, <5 days a week versus ≤45 minutes, <5 days a week	23.1 (SD 17.5) days	26.5 (SD 15.7) days	<ul style="list-style-type: none"> 3.4 days^(b) 15% higher

a) Initial sample size was 283 but only 172 participants had completed the 4-week assessment for the relevant comparisons.

b) Mean difference in length of hospital stay was not statistically significant between groups.

Figure 8: Length of stay (% reduction)

Abbreviations: CI = confidence interval; SD = standard deviation.

1 2.3.5.3 Other resource use

2 The committee also highlighted that there may be downstream cost savings with higher
3 intensity from reducing disability / increasing independence for example from reducing
4 residential or home care requirements and home adaptations.

5 Three studies assessing more intensive physiotherapy were included as economic evidence
6 in the review, all of which reported limited information on resource use other than direct
7 intervention costs. Chan 2015¹¹ only incorporated rehabilitation costs into the analysis and
8 assumed that there were no downstream cost differences between groups. Furthermore, the
9 analysis was based on a clinical study included in the sensitivity analysis as both trial arms
10 were less intensive compared to the model comparison (1-2 hours, <5 days per week versus
11 >45 minutes to 1 hour, <5 days per week).

12 Dohl 2020¹⁷ was a cost-consequence analysis that also had limited applicability as it was
13 based on a clinical study set in Norway³ with trial arms that do not align with the model (>45
14 minutes to 1 hour, 7 days per week versus ≤45 minutes, <5 days per week). However, the
15 analysis did collect patient level resource use (GP services, physiotherapy services (private
16 and public), primary care services (home health care and rehab/nursing homes) and hospital
17 care) in the 18-month follow-up period of the trial. The results found no differences between
18 the groups for total costs, or for EQ-5D-5L or Barthel Index scores. Regression results also
19 did not find a strong association between BI score and use of health care services (-0.003
20 (95% CI: -0.02-0.02; p>0.05), however this is not surprising given that both groups reported
21 high BI scores (96 out of 100) at baseline. Statistical analysis of differences between
22 resource use categories or costs were also not presented.

23 Fernandez-Garcia 2021²⁰ was the only study that included the same comparison used in the
24 model (1-2 hours of robot-assisted arm training or enhanced upper limb therapy (EULT), 5
25 days per week versus >45 minutes to 1 hour of usual care, 5 days per week) as it is based
26 on a clinical study that is used to inform the treatment effect in the base-case analysis.⁵⁵ This
27 study was a UK within-trial analysis that collected patient level resource use at baseline and
28 6 months post-randomisation and found no statistically significant difference in total costs
29 between EULT and usual care (mean difference: £665 (95% CI -£444 to £1,774; p=0.239)).
30 However, when intervention costs were removed, the average cost per participant was
31 higher in the usual care group for all areas of resource use (primary care, social care and

1 medication costs) except for secondary care and other NHS and social services. Resource
2 use estimates were not taken from this study however, as the mean difference in the Barthel
3 Index scores between the higher intensity and usual care groups was smaller (2-point
4 improvement in BI score) than the model estimate (4.86-point improvement in BI score),
5 which suggests that the study population does not sufficiently reflect the overall evidence
6 base.

7 Given the limitations of the economic evidence results, a targeted literature search was
8 conducted to identify evidence of long-term care cost reductions related to clinical outcomes
9 that could be used in the model. Studies that assessed acute care or hospital costs only
10 were excluded.

11 A 2017 systematic review⁶⁴ was identified that investigated the relationship between costs of
12 stroke and functional outcome, as measured by 90-day mRS scores. Inclusion criteria were
13 studies that focused on reported cost data for an acute stroke population (indirect and/or
14 direct costs i.e., hospital stay, medications, carer costs and loss of workplace earnings) with
15 mRS scores as the health outcome. The analysis found that costs consistently increased
16 with greater severity (increasing modified Rankin Scale score), however it was noted that
17 existing data were limited and only 4 of the 13 included studies reported costs by mRS
18 categories. The inclusion of only acute stroke populations limits the applicability of the results
19 for this model. One UK study identified from the systematic review was Luengo-Fernandez
20 2013,³⁹ which reported that annual post-acute (6 months post-stroke) total costs increased
21 as disability severity increased, with mean total costs of £2,135 for patients reporting mRS
22 scores lower than 3, £4,165 for mRS scores of 3 or 4 and £6,324 for those with an mRS of 5.
23 However, the study population was patients with atrial fibrillation with an average age of 80
24 years, suggesting that there may be additional comorbidities in this population, and the
25 follow-up period was between 2002–2007, which may not be representative of the intensity
26 model cohort or for current standards of care and as such, was not incorporated into the
27 analysis.

28 Considering that BI mapping was used to estimate QALYs in the analysis, and committee
29 consensus that a person's level of independence is likely to translate to different care needs
30 (and therefore costs), four studies identified in the targeted literature search that analysed
31 cost differences associated with BI score were explored. Dohl 2020 was one of these studies
32 and was subsequently not incorporated for reasons previously stated in this section, while
33 the second study (Fattore, 2012¹⁹) did support the association between BI and healthcare
34 costs but could not be used in the model as healthcare costs were reported based on BI
35 categories (mild (BI score: 75-95), moderate (BI score: 46-74) and severe dependence (BI
36 score: 0-45)), opposed BI scores alone.

37 The remaining two studies identified (O'Connor 2011⁴⁹ and Ganesh 2020²²) were then
38 presented to the committee to decide which should be used to capture downstream cost
39 savings.

40

41 Ganesh 2020 investigated the correlation between late improvement (measured by ≥ 1 mRS
42 grades, ≥ 1 RMI points, and/or ≥ 2 BI points between 3 and 12 months) and 5-year mortality,
43 institutionalization, and health and social care costs in a population-based cohort of 1-year
44 ischemic stroke survivors in the UK (Oxford Vascular Study 2002-2014). The study used
45 real-world data and conducted high-quality statistical analysis to explore the relationship
46 between improvements in outcomes and costs, specifically focusing on late improvers. The
47 study used data on health and social care resource use from the date of the first stroke in the
48 study period until 5 years post-stroke. The costs included health care costs, institutionalized

1 care (nursing home) costs, and hospital-based rehabilitation, including length of stay. The
2 authors found that for every 1-point improvement in BI (in the late improvers), there was a
3 saving of £2,795 (£4,753 to £837) in 5-year costs (converted to 2021 UK pounds from 2016
4 US dollars (\$) {, #21}). This results in a cost per week per BI point difference of £10.75, which
5 if applied to the pooled BI difference in the study of around 5, gives a saving of £57 per week
6 (~£3,000 per year if the difference were maintained). Unfortunately, the study did not capture
7 home care costs, which were considered to be a key source of cost impact by the committee.

8
9 O'Connor 2011 was a UK cost analysis of consecutive patients following a stroke (n=35)
10 admitted for multidisciplinary rehabilitation to the inpatient rehabilitation unit at the National
11 Demonstration Centre for Rehabilitation at the Leeds Teaching Hospitals NHS Trust over
12 one year. The study found that care costs fell as dependency decreased, and the median
13 estimated costs for care in the community were reduced from £1,900 to £1,100 per week,
14 reporting a saving of £868 per week. The study divided the cost saving per week by the
15 change in BI score to get a cost savings per BI point change, which could then be applied to
16 the pooled difference in BI score in the studies used in the model. This results in a cost of
17 £47 per week per BI point difference, which applied to the pooled BI difference in the model
18 of around 5, gives a saving of £248 per week (~£13,000 per year if the difference were
19 maintained). However, the study is small and not specifically designed to evaluate the cost
20 per change in BI and has not formally quantified this relationship. The costs were also
21 inflated from 1999 prices and were based on London rather than national unit costs.

22
23 The Ganesh 2020 and O'Connor 2011 studies provide valuable information on the
24 relationship between late improvement in BI and costs. While the Ganesh 2020 study is a
25 larger study with high-quality statistical analysis, it does not capture home care costs. The
26 O'Connor 2011 study is smaller, and the cost savings are theoretical, but it provides cost
27 savings per BI point difference that are more in line with those that the committee felt are
28 likely to be affected by improvement achieved by more intensive rehabilitation and was
29 therefore used in the base-case analysis.

30
31 Turner Stokes 1998⁶⁰ provided details about the care assessment tool used in O'Connor
32 (Northwick Park Dependency Scale (NPDS) and Care Needs Assessment (NPCNA) tool),
33 stating that it measures care needs, not care provision, and does not distinguish whether
34 care is provided by family members or outside agencies. The cost savings therefore reflect a
35 situation where all care needs are met and funded by the NHS and PSS. The committee felt
36 that accounting for all care needs was important. However, for the base-case analysis to be
37 in-line with the NICE reference case, costs not incurred by the NHS or PSS should be
38 removed. Information about what this proportion should be was not provided so it was
39 assumed to be 50%. A sensitivity analysis was done with all costs included and different
40 percentages attributable to NHS/PSS costs. Although the paper deriving care needs and
41 costs is potentially out of date, the committee noted that the tool is currently used within the
42 NHS and so the resource use estimates are still considered relevant. Costs have been
43 inflated using 2021 health care specific indices.³²

44
45 In two of the base case analyses post-rehab care savings were included and in the other two
46 base case analyses they were not included. The model assumes that the difference in BI
47 between the groups changes proportionally to the changes in EQ-5D that were modelled for
48 QALY estimation. This meant that in the scenarios where differences in EQ-5D disappearing
49 completely over time were modelled, the downstream cost savings will also disappear over

1 the same period, but in the scenario where EQ-5D differences are assumed to persist long
2 term, differences in downstream costs will also persist.

3 **2.3.5.4 Informal care costs**

4 The committee highlighted that a high proportion of care after stroke is provided by informal
5 carers and if dependence is reduced by high intensity rehabilitation this is likely to also
6 reduce the burden on carers.

7 NICE does not typically factor in the cost of informal or unpaid care into cost-effectiveness
8 evaluations of health interventions. However, the committee's view was that informal care
9 plays a crucial role in stroke rehabilitation. While a rapid review of the literature did provide
10 evidence suggesting that informal caregiving for stroke survivors is one of the largest cost
11 components for stroke^{8, 36}, sufficient data was not identified that could allow quantification of
12 changes in these costs with more intensive rehabilitation in the analysis.

2.4 **Computations**

14 The model was constructed in Microsoft Excel 2010 and was evaluated by cohort simulation.
15 Time dependency was built in by cross referencing the cohorts age as a respective risk
16 factor for mortality. Utility was also time dependent and was conditional on the age of the
17 population.

18 Patients start in cycle 0 in an alive health state. Patients moved to the dead health state at
19 the end of each cycle as defined by the mortality rate. The transition probability of dying was
20 determined by applying a standardised mortality ratio (SMR) to age-dependant general
21 population mortality rates from England life tables (ONS life tables for England 2017-19).

22 The QoL difference between higher and lower intensity physiotherapy (taking into account
23 baseline differences) was the treatment effect. This was based on studies in the clinical
24 review where reported outcomes had been mapped to EQ-5D-3L. The mapped EQ-5D
25 change scores (i.e., change from baseline in the higher intensity and lower intensity groups
26 from each study), were then meta-analysed using the inverse variance approach, alongside
27 the average age and intervention duration. Treatment effect was extrapolated beyond the
28 pooled trial data using two scenarios, due to uncertainty of the treatment effect as most
29 studies included in the analysis didn't report follow-up beyond 6 weeks: the first assumed a
30 weekly reduction in the EQ-5D mean difference between higher and lower intensity until no
31 difference was seen between the groups i.e., higher intensity speeds up health gains when
32 recovering from stroke. The second applied a weekly reduction to the mean difference for the
33 first 3 months post-intervention before assuming the difference was maintained for the
34 remaining lifetime i.e., higher intensity results in permanent health gains for stroke survivors.

35 A 1-week cycle length was used to allow physiotherapy rehabilitation costs and treatment
36 effects to be applied by week. Costs were calculated based on average resource use from
37 the trials and were pooled using a weighted average based on the number of participants
38 analysed in the study. Both base-case scenarios were modelled to generate results that
39 incorporated either intervention costs alone or with the assumption that higher intensity
40 physiotherapy produces ongoing care cost savings a on weekly basis stemming from a per-
41 point reduction in BI scores.

42 Mortality rates were converted into transition probabilities for the respective cycle length
43 (1 week) before inputting into the Markov model. The annual probability of death was

1 converted into a rate, before being converted into a probability appropriate for the cycle
2 length. The above conversions were done using the following formulae:

3

$Selected\ rate\ (r) = \frac{-\ln(1 - P)}{t}$	Where P =probability of event over time t t =time over which probability occurs (1 year)
$Transition\ Probability\ (P) = 1 - e^{-rt}$	Where r =selected rate t =cycle length (1 week)

4 Life years for the cohort were computed each cycle. To calculate QALYs for each cycle,
5 $Q(t)$, the time spent (i.e., 1 week or 0.02 years) in the alive state of the model was weighted
6 by a utility value that was dependent on the cycle, the long-term utility assumption being
7 employed and the treatment group. A half-cycle correction was applied. QALYs were then
8 discounted to reflect time preference (discount rate = r). QALYs during the first cycle were
9 not discounted. The total discounted QALYs was the sum of the discounted QALYs per
10 cycle.

11 Costs per cycle, $C(t)$, were calculated in the same way as QALYs. In the base case,
12 rehabilitation costs were applied to the first 6 cycles only. For scenarios that assumed
13 ongoing care cost-savings, this was applied in cycle 7 and beyond. Costs were discounted to
14 reflect time preference (discount rate 3.5% per year) in the same way as QALYs using the
15 following formula:

16 Discounting formula:

$Discounted\ total = \frac{Total}{(1 + r)^n}$	Where: r =discount rate per annum n =time (years)
---	---

17

2.5 Sensitivity analyses

19 2.5.1 Cohort settings

20 2.5.1.1 Cohort age

21 Sensitivity analyses using a cohort start age of 50, 60, 70, 80 and 90 years was done to
22 explore the impact of cohort age in the analysis.

23 2.5.1.2 Based on clinical studies used to inform treatment effects

24 A sensitivity analysis was done where the population entering the model was assigned a
25 start age of 63 years and 41% female based on a weighted average from the clinical studies
26 used to inform treatment effects instead of real-world data from the national stroke audit in
27 people that received physiotherapy (start age 75 years for women and 71 years for men, and
28 48% women).

1 **2.5.2 Mortality**

2 **2.5.2.1 Lower SMRs**

3 Sensitivity analysis was done where SMRs were reduced by 25% and 50% to reflect that
4 outcomes after stroke may have improved over time.

5 **2.5.3 Clinical studies used to inform treatment effect**

6 12 studies out of the 32 included in the clinical review for the >1 to 2 hours physiotherapy
7 category had data that could be used to inform QALY estimation for economic evaluation
8 (that is EQ-5D or BI). The 8 studies comparing >1 to 2 hours physiotherapy 5 days a week to
9 >45 minutes to 1 hour, 5 days a week were used in the base case analysis. A sensitivity
10 analysis was done using all 12 studies.

11 The additional study details and outcome available to map to EQ-5D-3L for each study are
12 summarised in Table 12.

13

14

15

Table 12: Additional clinical studies included in sensitivity analysis

Study	• N • Mean age • % female	Setting	Intervention	Last follow-up	EQ-5D/ BI	Area of focus	Time since stroke ^(a)	Stroke severity	Intervention intensity detail	Control arm detail	CEA?
Askim 2010 ⁴	<ul style="list-style-type: none"> • N=62 • 77 yrs • 53% 	Mixed (inpatient and post discharge settings) (Norway)	4 weeks	26 weeks	BI	Mixed: Upper limb and Lower limb, general physical function, functional independence	Subacute stroke	Not stated/ unclear	Three additional sessions each week for the first 4 weeks after discharge, followed by 1 additional session every week for the next 8 weeks, plus home exercises to be performed twice a day, 6 days a week	Physiotherapy emphasizing mobilization	No
Cooke 2010 ¹³	<ul style="list-style-type: none"> • N=109 • 63 yrs • 40% 	Inpatient (UK)	6 weeks	12 weeks	EQ-5D	Lower limb	Stroke (not specified)	Not stated/ unclear	Additional therapy (two different types of additional therapy for the same time period)	Usual care (conventional therapy only - time period likely 1 hour, 4 days a week)	Chan, 2015 ¹¹ (CUA)
Glasgow Augmented Physiotherapy Study 2004 ²³	<ul style="list-style-type: none"> • N=109 • 68 yrs • 41% 	Inpatient (Scotland)	4 weeks	3 months; 6 months	BI, EQ-5D	Mixed	Subacute stroke	Not stated/ unclear	Conventional physiotherapy and additional therapy	Conventional physiotherapy	No
Yoo 2013 ⁶⁵	<ul style="list-style-type: none"> • N=109 • 50 yrs • 41% 	Unclear setting (South Korea)	6 weeks	6 weeks	BI	Upper limb	Chronic stroke	not stated/ unclear	Robot assisted therapy (90 minutes, three times a week, six weeks)	Conventional therapy (60 minutes, three times a week, six weeks)	No

Abbreviations: BI = Barthel index; CEA = cost-effectiveness analysis; CUA = cost-utility analysis (QALYs as outcome measure); EQ-5D-5L – Euroqol 5 dimensions – 5 level version; SD = standard deviation

(a) Subacute stroke = 7 days – 6 months; Chronic stroke >6 months

1 Mapped EQ-5D-3L data from these studies was incorporated into the pooled estimate of end
2 of intervention treatment effect. The revised pooled data is shown in Table 13.

3 **Table 13: Sensitivity analysis: End of intervention pooled EQ-5D-3L treatment effect**

	Mean difference in CFBL (H – L)	Mean difference inverse variance weight ^(a)	Intervention duration (weeks)	Mean age	BL	CFBL-L
Studies included in base-case analysis						
Cabanas-Valdes 2016	0.1317	8.4%	5	76	0.131	0.251
Han 2013	-0.08	3.0%	6	53	0.384	0.236
Jiang 2020	0.032	9.9%	2	64	0.448	0.007
Kim 2016	-0.066	2.9%	4	66	0.366	0.279
Klassen 2020	-0.007	4.7%	4	57	0.476	0.278
Lee 2012	0.039	7.5%	4	54	0.400	0.042
Rodgers 2019	0.029	15.0%	12	61	0.222	0.047
Tollar 2021	0.1010	15.7%	5	67	0.363	0.166
Additional studies included in sensitivity analysis						
Askim 2010	-0.002	8.7%	4	77	0.473	0.161
Cooke 2010	0.072	4.8%	6	68	0.245	0.021
Glasgow 2004	-0.050	9.1%	4	68	0.371	0.183
Yoo 2013	0.003	10.3%	6	50	0.544	0.006
Pooled^(b)	0.064		6	65	0.34	0.13

4 Abbreviations: BL = base line; CFBL = change from baseline; EQ-5D-3L = EuroQol 5-dimension – 3 level version;
5 H = higher intensity; L = lower intensity.

6 a) Weights calculated from inverse variance (random effects assumption) of EQ-5D-3L mean difference in
7 CFBL with higher intensity compared to lower intensity physiotherapy.

8 b) Pooling is based on a weighted average using weights calculated for treatment effect based on inverse
9 variance.

10 Two of the additional studies did not show a gain in EQ-5D-3L at the end of the intervention
11 (Askim and Glasgow) and so were not considered useful to inform how differences changed
12 post-rehabilitation (as in the base case analysis). Cooke had a follow-up point at 12 weeks (6
13 weeks after the end of the study intervention) but there was high drop out in one of higher
14 intensity groups and a published CUA based on this trial did not use this data for this reason
15 and so the same approach has been taken here. Therefore, the base case model inputs are
16 used after the end of the intervention in this sensitivity analysis.

17 2.5.4 Post-intervention treatment effect and extrapolation

18 2.5.4.1 Shorter time horizon

19 Due to the uncertainty towards extrapolating effects in the longer term, sensitivity analyses
20 were done with shorter time horizons:

- 1 • An 18-week time horizon was selected to reflect the mean intervention time (6 weeks) and
2 the 12-week post-rehabilitation follow-up period, based on Rodgers 2019.⁵⁵
3 • A 2-year time horizon was selected as this was used in previous economic models and
4 required less extrapolation of the model inputs than the base case assumptions.

5 **2.5.4.2 Percentage change post-intervention**

6 The analyses were rerun using a percentage change (rather than an absolute change) per
7 week in the mean utility difference post-rehab with higher and lower intensity physiotherapy
8 based on data from Rodgers 2019. This results in a 5% reduction per week.

9 **2.5.5 Rehabilitation costs**

10 **2.5.5.1 Proportion of time rehabilitation assistant versus physiotherapist**

11 A sensitivity analysis was done to increase the proportion of rehabilitation assistants
12 delivering physiotherapy in the community to 50% compared with 25% in the base case.

13 **2.5.5.2 Staff costs**

14 A sensitivity analysis was done where staff unit costs were increased to account for
15 potentially higher costs associated with 7-day rehabilitation services, as shown in Table 14
16 below.

17 Note that it is unclear to what extent the unit costs in the base case already include overtime
18 payments.

19 **Table 14: Calculations for the estimated increase in salary costs for 7-day provision**

	Days per year ^(a)		Pay rate	
			Band 4-9	Band 3
Total	260	100%		
Saturday	12	5%	130%	135%
Sunday	12	5%	160%	169%
Week	236	91%	100%	100%
Weighted salary uplift			104%	105%

20 a) Assuming staff work one weekend a month with enhanced payments

21 **2.5.5.3 Number of staff required to deliver more intensive physiotherapy post-** 22 **discharge**

23 The average number of staff required to deliver more intensive physiotherapy post-discharge
24 was increased from to 1.5 per patient, as 1.33 was included in the base-case analysis based
25 on committee expert opinion.

1 2.5.5.4 Rehabilitation duration

2 A sensitivity analysis was done where the duration of rehabilitation was set to 10 weeks to
3 account for costs and treatment effects associated with clinical studies that reported a longer
4 treatment duration than the 6-week period applied in the base-case analysis.

5 2.5.6 Ongoing costs

6 2.5.6.1 Proportion of care costs funded by NHS/PSS

7 A sensitivity analysis was done with all costs included where different percentages (25% and
8 100%) of ongoing care costs were attributable to NHS/PSS costs. This was done because
9 the study used to incorporate post-rehabilitation care cost savings did not distinguish NHS
10 costs from care provided by family members or outside agencies.


11 2.5.6.2 Alternative data about longer term costs

12 A sensitivity analysis was done where cost savings per unit reduction in BI from Ganesh
13 2020²² were applied instead of O'Connor 2011.⁴⁹

14 2.5.7 Length of stay reduction

15 A sensitivity analysis was done including a length of stay saving based on studies that had a
16 1-2 hours per day high intensity group. Because the studies had longer average length of
17 inpatient stay than being used in the model, a percent reduction was applied rather than the
18 absolute reduction from the trials (see Figure 9). A reduction of 17% was applied using the
19 data from the category most close to that being considered in the model with rehabilitation 5
20 days a week. This reduction was then applied to the mean cost of inpatient rehabilitation,
21 estimated using the mean number of weeks applied in the base-case analysis (based on the
22 mean inpatient stay from national audit data)⁵⁷ and the cost per day in hospital (£266) (taken
23 from the 2022/23 National Tariff Payment System (NTPS)⁴⁷), which produced a total cost
24 saving of £791 for higher intensity physiotherapy.

Figure 9: Length of stay (% reduction)



Abbreviations: CI = confidence interval; SD = standard deviation.

25

2.6 Model validation

2 The model was developed in consultation with the committee; model structure, inputs and
3 results were presented to and discussed with the committee for clinical validation and
4 interpretation.

5 The model was systematically checked by the health economist undertaking the analysis;
6 this included inputting null and extreme values and checking that results were plausible given
7 inputs. The model was peer reviewed by a second experienced health economist from the
8 Guideline Development Team – National Guideline Centre; this included systematic checking
9 of many of the model calculations.

2.7 Estimation of cost effectiveness

11 The widely used cost-effectiveness metric is the incremental cost-effectiveness ratio (ICER).
12 This is calculated by dividing the difference in costs associated with 2 alternatives by the
13 difference in QALYs. The decision rule then applied is that if the ICER falls below a given
14 cost per QALY threshold the result is considered to be cost effective. If both costs are lower
15 and QALYs are higher the option is said to dominate and an ICER is not calculated.

$$ICER = \frac{Costs(B) - Costs(A)}{QALYs(B) - QALYs(A)}$$

Where: Costs(A) = total costs for option A; QALYs(A) = total QALYs for option A

Cost effective if:

- ICER < Threshold

2.8 Interpreting results

17 NICE sets out the principles that committees should consider when judging whether an
18 intervention offers good value for money.^{41, 42, 45} In general, an intervention was considered
19 to be cost effective if either of the following criteria applied (given that the estimate was
20 considered plausible):

- 21 • The intervention dominated other relevant strategies (that is, it was both less costly in
22 terms of resource use and more clinically effective compared with all the other relevant
23 alternative strategies), or
- 24 • The intervention costs less than £20,000 per quality-adjusted life-year (QALY) gained
25 compared with the next best strategy.

26

3 Results

3.1 Base case

3

4

5

6

The deterministic and probabilistic base case results are presented in Table 15 and Table 16. Probabilistic results are also presented graphically in Table 15:
Base-case analysis: mean costs and QALYs per person (deterministic analysis)

Analysis	Mean cost difference (H vs L)	Mean QALY difference (H vs L)	Incremental cost per QALY gained
Scenario 1: difference diminishes at an absolute rate seen in trials until no difference			
a) Intervention costs only	£2,286	0.02	£127,266
b) With post-rehab care savings	£452	0.02	£25,180
Scenario 2: difference diminishes up to 12 weeks post-intervention, then difference is maintained for lifetime			
a) Intervention costs only	£2,286	0.21	£10,841
b) With post-rehab care savings	-£24,201	0.21	Higher dominant

7

Abbreviations: H = higher intensity physiotherapy; L = lower intensity physiotherapy; QALY= quality-adjusted life year.

8

9

Table 16: Base-case analysis: mean costs and QALYs per person (probabilistic analysis)

Analysis	Mean cost difference (H-L)	Mean QALY difference (H-L)	Incremental cost effectiveness ratio (ICER)	% simulations H cost-effective (£20K/QALY)
Scenario 1: difference diminishes at an absolute rate seen in trials until no difference				
a) intervention costs only	£2,279	0.05	£48,539	7%
b) with post-rehab care savings	-£3,312	0.05	Higher dominant	76%
Scenario 2: difference diminishes up to 12 weeks post-intervention, then difference is maintained for lifetime				
a) intervention costs only	£2,286	0.24	£9,676	83%
b) with post-rehab care savings	-£29,487	0.24	Higher dominant	96%

Abbreviations: H = higher intensity physiotherapy; L = lower intensity physiotherapy; QALY= quality-adjusted life year.

10

Figure 10. Results are presented for four base case scenarios:

11

12

13

14

15

16

17

18

19

20

- Scenario 1 (weekly reduction of EQ-5D mean difference until no difference between was seen between higher and lower intensity groups, meaning higher intensity leads to faster stroke recovery),
 - a) intervention costs only
 - b) with post-rehabilitation care cost savings
- Scenario 2 (3-month weekly reduction applied before the difference was maintained, meaning higher intensity leads to permanent health gains).
 - a) intervention costs only
 - b) with post-rehabilitation care cost savings

1 In Scenario 1a, higher intensity physiotherapy was not cost-effective compared to lower
2 intensity, as the incremental cost effectiveness ratio (ICER) for the deterministic analysis was
3 £127,266 per QALY gained and £48,539 in the probabilistic analysis, with an 7% probability
4 of being cost-effective at a £20,000 NICE threshold. When post-rehabilitation care cost-
5 savings were incorporated Scenario 1b), higher intensity physiotherapy was remained not
6 cost-effective in the deterministic analysis (ICER of £25,180) but was dominant in the
7 probabilistic analysis (lower costs and improved quality of life) when compared to lower
8 intensity physiotherapy, with a 76% probability of being cost-effective.
9

10 The results showed that with Scenario 2a, higher intensity physiotherapy was cost-effective
11 for both the deterministic (ICER of £10,841) and probabilistic analyses (ICER of £9,676), with
12 an 83% probability of being cost-effective compared to lower intensity physiotherapy.
13 Moreover, higher intensity physiotherapy was dominant compared to lower intensity following
14 the inclusion of post-rehabilitation care cost-savings in both the deterministic and
15 probabilistic analyses, with a 96% probability of being cost-effective.
16

1

2 **Table 15: Base-case analysis: mean costs and QALYs per person (deterministic analysis)**

Analysis	Mean cost difference (H vs L)	Mean QALY difference (H vs L)	Incremental cost per QALY gained
Scenario 1: difference diminishes at an absolute rate seen in trials until no difference			
a) Intervention costs only	£2,286	0.02	£127,266
b) With post-rehab care savings	£452	0.02	£25,180
Scenario 2: difference diminishes up to 12 weeks post-intervention, then difference is maintained for lifetime			
a) Intervention costs only	£2,286	0.21	£10,841
b) With post-rehab care savings	-£24,201	0.21	Higher dominant

3 Abbreviations: H = higher intensity physiotherapy; L = lower intensity physiotherapy; QALY= quality-adjusted life year.


4

5 **Table 16: Base-case analysis: mean costs and QALYs per person (probabilistic analysis)**

Analysis	Mean cost difference (H-L)	Mean QALY difference (H-L)	Incremental cost effectiveness ratio (ICER)	% simulations H cost-effective (£20K/QALY)
Scenario 1: difference diminishes at an absolute rate seen in trials until no difference				
a) intervention costs only	£2,279	0.05	£48,539	7%
b) with post-rehab care savings	-£3,312	0.05	Higher dominant	76%
Scenario 2: difference diminishes up to 12 weeks post-intervention, then difference is maintained for lifetime				
a) intervention costs only	£2,286	0.24	£9,676	83%
b) with post-rehab care savings	-£29,487	0.24	Higher dominant	96%

Abbreviations: H = higher intensity physiotherapy; L = lower intensity physiotherapy; QALY= quality-adjusted life year.


1 **Figure 10: Base case results (Scenario 1a with only intervention costs applied): cost-**
 2 **effectiveness plane for higher intensity vs lower intensity**



3
4
5

Scenario 1a: weekly reduction of EQ-5D mean difference until no difference between was seen between higher and lower intensity groups, meaning higher intensity leads to faster stroke recovery.


6 **Figure 11: Base case results (Scenario 1b with post-rehabilitation cost savings): cost-**
 7 **effectiveness plane for higher intensity vs lower intensity**



8
9
10


Scenario 1b: weekly reduction of EQ-5D mean difference until no difference between was seen between higher and lower intensity groups, meaning higher intensity leads to faster stroke recovery.

1 **Figure 12: Base case results (Scenario 2a with only intervention costs applied): cost-**
 2 **effectiveness plane for higher intensity vs lower intensity**



3
 4 Scenario 2a: (3-month weekly reduction applied before the difference was maintained, meaning higher intensity leads to
 5 permanent health gains).

6 **Figure 13: Base case results (Scenario 2b with post-rehabilitation cost savings): cost-**
 7 **effectiveness plane for higher intensity vs lower intensity**



8
 9 Scenario 2b: 3-month weekly reduction applied before the difference was maintained, meaning higher intensity leads to
 10 permanent health gains.
 11

1 **3.1.1 Differences between deterministic and probabilistic results**

2 The mean costs and QALYs from the probabilistic analysis are usually considered the best
3 estimate for use in decision making. Deterministic and probabilistic results are often very
4 similar (as the mean of each model inputs is the point estimate). However, this is not always
5 the case, if models are non-linear.

6 The deterministic analysis (using the input point estimates and not the uncertainty around
7 them) is also calculated and it is routine to consider if these are similar, and if not why, to
8 ensure there are no programming errors in the model.

9 Comparing Table 15 with Table 16, the QALY gains are larger in the probabilistic analyses
10 than in the deterministic analyses, particularly in Scenario 1a and 1b, where the utility gain
11 converges to zero over time. The post-rehab cost savings are also greater in the probabilistic
12 analyses because they are explicitly correlated with the utility gain. In the case of Scenario
13 1B this meant that higher intensity cost more than £20,000 per QALY in the deterministic
14 analysis but was dominant in the probabilistic analysis.

15 The reason that the probabilistic QALYs are larger seems to be due to:

- 16 a) When the absolute change is low the improvement in QALYs is pushed off into the
17 future, but this is discounted (creating a non-linearity).
- 18 b) Also, when the absolute change is very low there isn't enough cycles in the model for
19 convergence of utility to take place and therefore for some simulations there remains
20 a significant improvement in utility over the whole lifetime.

21 The probabilistic results should take precedence over the deterministic ones because:

- 22 • Discounting is a fundamental part of the NICE reference case.
- 23 • It is plausible that the utilities don't converge.
- 24 • The assumption about the absolute change in the analysis is already conservative by
25 using a gamma distribution for the absolute change. This constrains it in favour of
26 less intensive therapy even though the confidence interval crossed zero.

27 Therefore, the sensitivity analyses that follow are all calculated probabilistically.

28

3.2 Sensitivity analyses

30 A number of sensitivity analyses were conducted and are described in section 2.5, with Table
31 17Table 20 below presenting the results. Sensitivity analyses were applied to each of the 4
32 base-case scenarios and each one was conducted probabilistically.

33

34 The results for Scenario 1a (Table 17) remained not cost-effective for higher intensity
35 physiotherapy across all sensitivity analyses, which was unsurprising considering that this
36 was the most conservative option out of the base-case scenarios.

37

38 The results were also robust for Scenario 2a, as **Error! Reference source not found.**
39 showed that higher intensity physiotherapy remained cost-effective across most sensitivity
40 analyses with the exception of

- 41 • an initial cohort age of 90 years (ICER of £38,472 per QALY gained),
- 42 • the 18-week time horizon (£181,443 per QALY gained) and
- 43 • 2-year time horizon (£36,382 per QALY gained).

1 This was expected as an older model cohort and shorter time horizons prevent the inclusion
2 of long-term utility benefits.
3
4 For Scenario 1b (**Error! Reference source not found.**), higher intensity physiotherapy
5 remained dominant compared to usual care for most sensitivity analyses: exceptions to this
6 included:
7 • an 18-week time horizon, which resulted in higher intensity being not cost-effective
8 (£73,059 per QALY gained),
9 • alternative data for post-rehabilitation care cost savings from Ganesh 2020 suggested
10 that higher intensity had a 43% probability of being cost-effective compared to lower
11 intensity at a £20,000 threshold (£233 per QALY gained).
12 The probability of higher intensity physiotherapy being cost-effective was also reduced to
13 48% when the proportion of post-rehabilitation care cost savings incurred by the NHS/PSS
14 was set to 25% (however these costs would still be incurred by the individual or their families
15 despite their exclusion from this analysis).
16 Table 20 presents the results for Scenario 2, where higher intensity physiotherapy remained
17 dominant compared to lower intensity for all scenarios, apart from when an 18-week time
18 horizon was applied (ICER of £83,543).
19

1

2 **Table 17: Sensitivity analyses for Scenario 1a**

Analysis	Mean cost difference (H vs L)	Mean QALY difference (H vs L)	Incremental cost per QALY	Probability CE @£20K
Scenario 1: difference diminishes at an absolute rate seen in trials until no difference (with intervention costs only)				
Base case	£2,279	0.05	£48,539	7%
Cohort settings				
Cohort age 63 and 41% female based on clinical studies	£2,300	0.05	£44,602	7%
Cohort initial age = 50 years	£2,296	0.07	£34,727	10%
Cohort initial age = 60 years	£2,277	0.06	£39,074	10%
Cohort initial age = 70 years	£2,292	0.05	£45,070	10%
Cohort initial age = 80 years	£2,283	0.04	£59,417	5%
Cohort initial age = 90 years	£2,229	0.03	£86,417	0%
SMRs 25%	£2,290	0.05	£45,636	9%
SMRS 75%	£2,296	0.06	£38,694	9%
Treatment effect				
Alternative clinical data: all PT studies where the intervention was >1 to 2 hours physiotherapy	£2,283	0.06	£37,588	10%
Difference diminishes at constant % instead of constant absolute change	£2,281	0.05	£42,903	6%
Time horizon				
18-week (6+12) time horizon	£2,275	0.01	£180,998	0%
2-year time horizon	£2,281	0.03	£66,484	2%
Costs				
50% RA in community	£2,164	0.05	£45,943	9%
Higher staff costs (PT 104%/ RA 105%)	£2,398	0.05	£49,408	7%
Average number of staff required: 2 inpatient / 1.5 post-charge	£2,436	0.05	£52,767	7%
Length of stay reduction applied	£1,495	0.05	£30,788	20%
Rehabilitation duration				
10 weeks	£3,801	0.05	£77,724	3%

3

4

5

Abbreviations: CE @£20K = cost-effective at £20,000 per QALY gained; PSS= personal social services; PT= physiotherapist; QALY= quality-adjusted life year; RA= rehabilitation assistants; SMR= standardised mortality ratio

6

7

1

2 **Table 18: Sensitivity analyses for Scenario 1b**

Analysis	Mean cost difference (H vs L)	Mean QALY difference (H vs L)	Incremental cost per QALY gained	Probability CE @£20K
Scenario 1a- Difference diminishes until no difference (with post-rehabilitation cost savings)				
Base case	-£3,401	0.05	Higher dominant	76%
Cohort settings				
Cohort age 63 and 41% female based on clinical studies	-£4,168	0.06	Higher dominant	84%
Cohort initial age = 50 years	-£4,841	0.07	Higher dominant	88%
Cohort initial age = 60 years	-£4,067	0.05	Higher dominant	85%
Cohort initial age = 70 years	-£3,371	0.05	Higher dominant	78%
Cohort initial age = 80 years	-£2,760	0.04	Higher dominant	70%
Cohort initial age = 90 years	-£1,340	0.03	Higher dominant	59%
SMRs 25%	-£3,645	0.05	Higher dominant	78%
SMRS 75%	-£5,941	0.06	Higher dominant	88%
Treatment effect				
Alternative clinical data: all PT studies where the intervention was >1 to 2 hours physiotherapy	-£6,500	0.06	Higher dominant	86%
Difference diminishes at constant % instead of constant absolute change	-£3,930	0.05	Higher dominant	86%
Time horizon				
18-week (6+12) time horizon	£916	0.01	£73,059	14%
2-year time horizon	-£1,757	0.03	Higher dominant	62%
Costs				
50% RA in community	-£3,135	0.05	Higher dominant	78%
Higher staff costs (PT 104%/ RA 105%)	-£3,571	0.05	Higher dominant	77%
Average number of staff required: 2 inpatient / 1.5 post-charge	-£3,150	0.05	Higher dominant	74%
Length of stay reduction applied	-£4,749	0.05	Higher dominant	89%
Care costs NHS/PSS 25%	-£613	0.05	Higher dominant	48%
Care costs NHS/PSS 100%	-£8,373	0.04	Higher dominant	93%
Alternative post-rehabilitation savings data (Ganesh)	£10	0.05	£223	43%
Rehabilitation duration				
10 weeks	-£1,795	0.05	Higher dominant	50%

3 Abbreviations: CE @£20K = cost-effective at £20,000 per QALY gained; PSS= personal social services; PT=
4 physiotherapist; QALY= quality-adjusted life year; RA= rehabilitation assistants; SMR= standardised mortality
5 ratio

6

1 **Table 19: Sensitivity analyses for Scenario 2a**

Analysis	Mean cost difference (H vs L)	Mean QALY difference (H vs L)	Incremental cost per QALY gained	Probability CE @£20K
Scenario 2a - Difference diminishes up to 12 weeks post-intervention, then difference maintained for lifetime (with intervention costs only)				
Base case	£2,286	0.24	£9,676	83%
Cohort settings				
Cohort age 63 and 41% female based on clinical studies	£2,302	0.388	£5,926	90%
Cohort initial age = 50 years	£2,295	0.585	£3,925	91%
Cohort initial age = 60 years	£2,273	0.426	£5,340	90%
Cohort initial age = 70 years	£2,283	0.286	£7,981	87%
Cohort initial age = 80 years	£2,282	0.145	£15,765	67%
Cohort initial age = 90 years	£2,249	0.058	£38,472	3%
SMRs 25%	£2,293	0.272	£8,426	87%
SMRS 75%	£2,287	0.516	£4,435	91%
Treatment effect				
Alternative clinical data: all PT studies where the intervention was >1 to 2 hours physiotherapy	£2,290	0.51	£4,499	91%
Difference diminishes at constant % instead of constant absolute change	£2,284	0.41	£5,638	80%
Time horizon				
18-week (6+12) time horizon	£2,291	0.01	£181,443	0%
2-year time horizon	£2,298	0.06	£36,382	4%
Costs				
50% RA in community	£2,151	0.24	£9,000	85%
Higher staff costs (PT 104%/ RA 105%)	£2,373	0.24	£9,939	83%
Average number of staff required: 2 inpatient / 1.5 post-charge	£2,425	0.23	£10,386	83%
Length of stay reduction applied	£1,502	0.24	£6,274	89%
Rehabilitation duration				
10 weeks	£3,820	0.23	£16,434	64%

2 Abbreviations: CE @£20K = cost-effective at £20,000 per QALY gained; PSS= personal social services; PT=
3 physiotherapist; QALY= quality-adjusted life year; RA= rehabilitation assistants; SMR= standardised mortality
4 ratio

5
6

1

2 **Table 20: Sensitivity analyses for Scenario 2b**

Analysis	Mean cost difference (H vs L)	Mean QALY difference (H vs L)	Incremental cost per QALY gained	Probability CE @£20K
Scenario 2b - Difference diminishes up to 12 weeks post-intervention, then difference is maintained for lifetime (with post-rehabilitation cost savings)				
Base case	-£29,487	0.24	Higher dominant	96%
Cohort settings				
Cohort age 63 and 41% female based on clinical studies	-£47,624	0.39	Higher dominant	98%
Cohort initial age = 50 years	-£70,338	0.58	Higher dominant	99%
Cohort initial age = 60 years	-£49,255	0.43	Higher dominant	98%
Cohort initial age = 70 years	-£35,066	0.28	Higher dominant	97%
Cohort initial age = 80 years	-£16,469	0.14	Higher dominant	95%
Cohort initial age = 90 years	-£6,091	0.06	Higher dominant	91%
SMRs 25%	-£32,463	0.27	Higher dominant	97%
SMRS 75%	-£63,991	0.51	Higher dominant	98%
Treatment effect				
Alternative clinical data: all PT studies where the intervention was >1 to 2 hours physiotherapy.	-£63,328	0.52	Higher dominant	98%
Difference diminishes at constant % instead of constant absolute change	-£45,642	0.39	Higher dominant	97%
Time horizon				
18-week (6+12) time horizon	£1,035	0.01	£83,543	13%
2-year time horizon	-£5,861	0.07	Higher dominant	91%
Costs				
50% RA in community	-£28,907	0.24	Higher dominant	97%
Higher staff costs (PT 104%/ RA 105%)	-£28,185	0.24	Higher dominant	97%
Average number of staff required: 2 inpatient / 1.5 post-charge	-£29,397	0.23	Higher dominant	96%
Length of stay reduction applied	-£29,783	0.24	Higher dominant	98%
Care costs NHS/PSS 25%	-£13,544	0.24	Higher dominant	94%
Care costs NHS/PSS 100%	-£59,838	0.23	Higher dominant	99%
Alternative post-rehabilitation savings data (Ganesh)	-£10,567	0.24	Higher dominant	94%
Rehabilitation duration				
10 weeks	-£28,516	0.23	Higher dominant	94%

3
4
5
6

Abbreviations: CE @£20K = cost-effective at £20,000 per QALY gained; PSS= personal social services; PT= physiotherapist; QALY= quality-adjusted life year; RA= rehabilitation assistants; SMR= standardised mortality ratio

4 Discussion

4.1 Summary of results

- 3 An original cost effectiveness analysis compared intensive therapy (1 to 2 hours, 5 days a
4 week) with less intensive therapy (<45 minutes, 5 days a week) for the following scenarios:
- 5 • Scenario 1 The difference in utility disappears over time.
 - 6 ○ a) intervention costs only
 - 7 ○ b) with post-rehabilitation care cost savings
 - 8 • Scenario 2 The difference in utility is maintained.
 - 9 ○ a) intervention costs only
 - 10 ○ b) with post-rehabilitation care cost savings

11 In each of these base case analyses, higher intensity physiotherapy was either cost-effective
12 or dominant compared to lower intensity physiotherapy, with the exception of the most
13 conservative scenario, 1a, (where £48,539 per QALY gained was the probabilistic result).

14 The results of each scenario were robust to changes in other model parameters except that:

- 15 • when there was a 2-year time horizon, both QALY gains and cost savings were
16 reduced, and high intensity was no longer cost effective in Scenario 2a;
- 17 • when there was an 18-week time horizon, high intensity was no longer cost effective
18 in Scenarios 1b, 2a and 2b; and
- 19 • if the cohort was aged 90, higher intensity was no longer cost effective in Scenario
20 2a.

4.2 Limitations and interpretation

22 **Limited availability of evidence usable for cost-effectiveness analysis**

23 Only 12 of 32 studies included in the clinical review reported the same intensity of
24 physiotherapy that could be used in the cost effectiveness analysis, with only 8 studies
25 reporting the same for levels of higher and lower intensity, respectively. Studies assessing
26 other forms of rehabilitation (multi-disciplinary team-delivered, speech and language,
27 occupational, and cognitive therapy) did not collect sufficient data that could be incorporated
28 into an economic analysis.

29 **Differences between trials informing evidence of effect**

30 The issue of whether more intensive therapy provides better outcomes for patients a critical
31 one for stroke rehabilitation. However, the evidence available to inform this question was
32 limited. The committee discussed at length how best to gather clinical evidence to help
33 inform this and agreed that the best strategy was to take an inclusive approach in order to try
34 and maximise the evidence available to help inform this question. The review therefore
35 included any study that compared more physiotherapy time with less irrespective of what
36 happened during this time and irrespective of setting. This evidence has therefore been used
37 in this cost-effectiveness analysis as our best available estimate of the treatment effect of
38 more intensive physiotherapy rehabilitation. However, this means that the studies used vary
39 in a number of ways:

- 1 • Setting: 4 studies^{9, 24, 31, 34} assessed interventions conducted in inpatients
2 rehabilitation settings, while 2 studies^{55, 59} were based in outpatient clinics and one
3 study did not specify the rehabilitation setting³⁷
4 • Time since stroke and stroke severity: most studies reported that participants were in
5 the subacute phase of stroke (7 days to 6 months), however Rodgers was based on a
6 chronic stroke population. People in the subacute phase may require more care
7 which would impact the intervention costs.
8 • Interventions used: the clinical review included any study deemed to have more
9 physiotherapy, even for specific intervention were provided in that time. For instance,
10 Rodgers 2019 included robot-assisted arm training, while Tollar 2021 assessed
11 exergame sessions that required the use of an Xbox. However, these costs were not
12 incorporated into the analysis.
13 • Delivery, frequency, and duration of intervention: 4 of the 8 clinical studies included in
14 the review did not specify whether the intervention was delivered on an individual or
15 group-basis (see Table 10), which creates uncertainty as group-based interventions
16 will incur lower staff costs. 2 studies did specify that that they were group-based while
17 another (Rodgers, 2019) specified that it was delivered to participants individually.
18 This study also reported that additional time for high intensity was not spread evening
19 over week was 3 additional sessions per week over usual care.

20 **Uncertainty about long term effects**

21 A crucial issue for interpreting this analysis is what happens in the long term, specifically,
22 whether more intensive rehabilitation leads to permanent differences that persist a lifetime or
23 simply speed up recovery. The clinical study included in the model that reported the longest
24 follow-up period available was 6 months,⁵⁵ which was 3 months after the end of the study
25 intervention. This showed a diminishing difference between the more and less intensive
26 groups but there remained a difference at the last follow-up. The committee discussed this
27 issue in detail and agreed that it was simply unknown whether the treatment effect would
28 continue to diminish or be maintained. This is a key area of uncertainty for the study
29 conclusions as Scenarios 1 and 2 reported different results when only intervention costs
30 were included, which was another area of uncertainty in the model.

31 **Lack of evidence about effects on carers**

32 Effects on carers have not been captured in this analysis. The committee highlighted that the
33 burden on carers is high and that interventions that could improve independence of the
34 person who has had a stroke also had the potential to reduce this burden. Evidence about
35 this was sought in the clinical review but none was available and so this potential effect is not
36 captured in the analysis. Evidence was also sought about the relationship between the
37 disability of the person who has had a stroke and carer quality of life. However, evidence was
38 mixed about whether there was a relationship, and no studies were identified that could be
39 used to model the impact in the cost-effectiveness analysis.

40 **Limitations in evidence about the effects on length of stay**

41 The committee agreed that higher intensity physiotherapy was likely to lead to people
42 meeting the functional goals required for discharge sooner. However, no evidence about
43 length of stay was identified in the studies included in the clinical review. In the base case
44 analysis, there was assumed to be no reduction in length of stay. The results did not seem to
45 be sensitive to this assumption.

1 Additional costs of rehabilitation

2 The studies used to inform treatment effects in the model often did not provide details about
3 how physiotherapy was delivered in the study and so it was unclear how many staff
4 members were required. The committee highlighted that it was common that more than one
5 staff member would be required to deliver physiotherapy, particularly initially. Some people
6 would only need 1 person, some 2 and some may even need 3 or 4. In addition it may be
7 that some physiotherapy may be delivered in a group setting, although this was considered
8 fairly uncommon.

9 Limited evidence about the downstream effects on costs

10

11 The effect of post-intervention cost savings is uncertain, which is unfortunate as this is
12 important in determining cost-effectiveness. The committee highlighted that improving
13 functional ability has the potential to lead to substantial cost savings, for example if less
14 nursing care is required or fewer home adjustments. Only two studies were identified as
15 appropriate for the estimation of the effects of stroke severity on post-rehabilitation
16 healthcare resource use. The study used in the base-case analysis (O'Connor 2011)
17 estimated theoretical cost-savings as it measured care needs, not care provision, which
18 necessitated an assumption to be applied for the proportion of care that would be provided
19 for by the NHS. The results for Scenario 1b proved to be sensitive to changes to post-
20 rehabilitation cost-savings as the probability of higher intensity physiotherapy being cost-
21 effective was below 50% when the proportion of post-rehabilitation care cost savings
22 incurred by the NHS/PSS was set to 25% and alternative care-cost savings data from
23 Ganesh 2020 were applied.

24 The committee also highlighted savings from returning to work in terms of reduced benefit
25 payments, however this was not incorporated into the analysis as it is not part of the NICE
26 reference-care perspective (and if a wider societal perspective were taken it would be a
27 transfer cost).

28 Duration of rehabilitation

29 We used a duration of rehabilitation of 6 weeks in the analysis when applying treatment
30 effects and calculating rehabilitation costs as this was the weighted average from the trials
31 used. Real-world data taken from SSNAP²⁵ shows that the actual duration of rehabilitation is
32 longer (see Table 21), suggesting that the intervention costs would be higher than what was
33 assumed for the base-case analysis, if the higher intensity was to be applied throughout
34 rehabilitation for all patients. However, the results were not sensitive to this assumption.

35 **Table 21: Duration of rehabilitation reported in SSNAP 2022**

Rehabilitation setting	Mean LOS		Median (IQR)	
	Days	Weeks	Days	Weeks
Inpatient stay	17.5	2.5	7.1 (IQR 2.8 to 21.9)	1.0 (IQR: 0.4 to 3.1)
ESD/community team	54.9	7.8	41 (IQR 21.1 to 69)	5.9 (IQR: 3.0 to 9.9)
Inpatient + ESD/community team	72.4	10.3		

1 Abbreviations: ESD= early supported discharge; LOS= length of stay; IQR= interquartile range; SSNAP= The Sentinel Stroke
2 National Audit Programme.

3 **Comparator**

4 The analysis looks at the cost-effectiveness of increasing the recommended amount of
5 physiotherapy time post-stroke using studies that compared physiotherapy for five days per
6 week for 1-2 hours versus >45 minutes to 1 hour. Although the current recommendation is for
7 at least 45 minutes of each therapy 5 days a week (in those that can tolerate it), SSNAP data
8 suggests that people are not always receiving this. In the inpatient setting it is reported that
9 physiotherapy is received by the patient on 72.6% of days in hospital out of the period the
10 patient requires physiotherapy, and the median number of minutes receive is 35 (IQR 29.6 –
11 45). In the community it is less, with 63% receiving physiotherapy in the required period and
12 the median number of minutes receive is 29 (IQR 27 – 41). This suggests that the benefits of
13 more intensive therapy could be greater than estimated by the model but so too would be the
14 resource impact (both in terms of therapist time and potential care savings).

4.3 **Generalisability to other populations or settings**

16 This cost effectiveness analysis is taken from a UK NHS setting. The model used NHS
17 reference costs and the cost effectiveness of higher intensity physiotherapy was assessed
18 using NICE's £20,000 threshold. Therefore, the results of this cost effectiveness analysis
19 may not be transferable to other countries or settings.

20 The model evaluated the cost effectiveness of increased intensity of *physiotherapy*. The
21 results do not apply to other forms of therapy. For the other forms of therapy there was not
22 enough clinical evidence to assess the effectiveness and cost effectiveness of increased
23 intensity.

4.4 **Comparisons with published studies**

25 Two studies comparing physiotherapy interventions were included as economic evidence for
26 this question, with neither analysis incorporating a lifetime horizon.

27 One study was a UK published economic evaluation²⁰ which assessed a 12-week
28 intervention and found that usual care dominated both higher-intensity physiotherapy groups
29 at 6-months follow-up (where participants received usual care plus robot-assisted arm-
30 training or enhanced upper limb therapy (EULT)), with EULT costing £74,100 per QALY
31 gained compared to usual care and a 19% probability being cost-effective at a £20,000 per
32 QALY threshold. In a sensitivity analysis where the trial data on costs and outcomes was
33 extrapolated to 12-months the ICER was £6,095 per QALY gained for EULT compared to
34 usual care, however this result was paired with only 55% probability of being cost-effective
35 (Robot-assisted arm training remained not cost-effective under all sensitivity analyses). This
36 analysis was limited as it was based on a single trial and not the wider evidence base
37 identified for this review. The trial used in this study was also incorporated into this economic
38 analysis for the pooled treatment-effect of higher intensity physiotherapy.⁵⁵

39 The second study included in the review for this topic was a Canadian cost-utility analysis¹¹
40 that assessed a 6-week intervention with an 18-week follow-up period, where participants
41 received either additional conventional physiotherapy or functional strength training
42 alongside conventional strength training. The base-case analysis assumed the between-
43 group utility difference at 6 weeks would be sustained at 1 year and then gradually decline

1 until no difference remained at 2-years post-intervention. 18-week utilities were not included
2 in the base-case since a greater number of participants were lost to follow-up in the usual
3 care group. The results found that both higher-intensity physiotherapy groups dominated
4 usual care, with cost savings of £1,520 and £1,369 and QALY gains of 0.05 and 0.12 for
5 additional conventional physiotherapy and functional strength training groups, respectively.
6 Dominance compared to usual care remained following a sensitivity analysis that reduced
7 the duration of effect to 1-year, while applying the 18-week follow-up results reported lower
8 costs and lower over QALYs for higher intensity physiotherapy. A key limitation of the
9 analysis was the inclusion of hospital bed-days saved from providing the higher intensity
10 interventions, as this was based on expert opinion and was the main driver of cost savings.
11 The analysis was partially applicable due to the use of 2010 Canadian resource estimates
12 and 2013-unit costs which may not reflect the current UK NHS context. A 5% discount rate
13 for costs and outcomes was also applied when 3.5% is the preferred rate by NICE. The trial
14 used in this study was also incorporated into a sensitivity analysis for the pooled treatment-
15 effect of higher intensity physiotherapy.¹³

4.5 Conclusions

17 Higher intensity physiotherapy (1 to 2 hours, 5 days a week) has been found to be cost
18 effective in the post-stroke adult population when post-rehabilitation care cost savings are
19 assumed, however this is highly dependent on assumptions made about the treatment effect
20 over time and magnitude of post-rehabilitation care cost-savings. The heterogeneity of the
21 studies, and the specific studies used, should be considered when interpreting this analysis.

4.6 Implications for future research

23 This analysis has shown that more intensive physiotherapy (1 to 2 hours, 5 days a week) is
24 likely to be cost effective. However, if more trials are undertaken, it would be helpful if they
25 assessed the direct impact on utility measures, so that economic evaluations are less
26 dependent on mapping studies. In addition, trials should make efforts to minimise missing
27 data.
28

1 **References**

2

- 3 1. An M, Shaughnessy M. The effects of exercise-based rehabilitation on balance and
4 gait for stroke patients: a systematic review. *The Journal of neuroscience nursing :
5 journal of the American Association of Neuroscience Nurses*. 2011; 43(6):298-307
- 6 2. Ara R, Brazier JE. Populating an economic model with health state utility values:
7 moving toward better practice. *Value in Health*. 2010; 13(5):509-518
- 8 3. Askim T, Langhammer B, Ihle-Hansen H, Gunnes M, Lydersen S, Indredavik B.
9 Efficacy and Safety of Individualized Coaching After Stroke: the LAST Study (Life
10 After Stroke). A pragmatic randomized controlled trial. 2018; 49(2):426-432
- 11 4. Askim T, Morkved S, Engen A, Roos K, Aas T, Indredavik B. Effects of a community-
12 based intensive motor training program combined with early supported discharge
13 after treatment in a comprehensive stroke unit: a randomized, controlled trial. *Stroke*.
14 2010; 41(8):1697-1703
- 15 5. Barendregt JJ. The effect size in uncertainty analysis. *Value in Health*. 2010;
16 13(4):388-391
- 17 6. Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T et al. A
18 systematic review, psychometric analysis and qualitative assessment of generic
19 preference-based measures of health in mental health populations and the estimation
20 of mapping functions from widely used specific measures. *Health Technology
21 Assessment*. 2014; 18(34):vii-viii, xiii-xxv, 1-188
- 22 7. Brønnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of
23 death after stroke. *Stroke*. 2001; 32(9):2131-2136
- 24 8. Brown DL, Boden-Albala B, Langa KM, Lisabeth LD, Fair M, Smith MA et al.
25 Projected costs of ischemic stroke in the United States. *Neurology*. 2006; 67(8):1390-
26 1395
- 27 9. Cabanas-Valdes R, Bagur-Calafat C, Girabent-Farres M, Caballero-Gomez FM,
28 Hernandez-Valino M, Urrutia Cuchi G. The effect of additional core stability exercises
29 on improving dynamic sitting balance and trunk control for subacute stroke patients: a
30 randomized controlled trial. *Clinical Rehabilitation*. 2016; 30(10):1024-1033
- 31 10. Carod-Artal FJ, Ferreira Coral L, Trizotto DS, Menezes Moreira C. Burden and
32 perceived health status among caregivers of stroke patients. *Cerebrovascular
33 Diseases*. 2009; 28(5):472-480
- 34 11. Chan B. Effect of Increased Intensity of Physiotherapy on Patient Outcomes After
35 Stroke: An Economic Literature Review and Cost-Effectiveness Analysis. *Ontario
36 Health Technology Assessment Series*. 2015; 15(7):1-43
- 37 12. Chen Y, Lu J, Wong KS, Mok VC, Ungvari GS, Tang WK. Health-related quality of life
38 in the family caregivers of stroke survivors. *International Journal of Rehabilitation
39 Research*. 2010; 33(3):232-237

- 1 13. Cooke EV, Tallis RC, Clark A, Pomeroy VM. Efficacy of functional strength training on
2 restoration of lower-limb motor function early after stroke: phase I randomized
3 controlled trial. *Neurorehabilitation and Neural Repair*. 2010; 24(1):88-96
- 4 14. Curtis L, Burns A. Unit costs of health and social care 2015. Canterbury. Personal
5 Social Services Research Unit University of Kent, 2015. Available from:
6 <http://www.pssru.ac.uk/project-pages/unit-costs/2015/>
- 7 15. Dakin H, Abel L, Burns R, Yang Y. HERC database of mapping studies, Version 8.0
8 (Last updated: 14th October 2020). 2020. Available from:
9 <http://www.herc.ox.ac.uk/downloads/herc-database-of-mapping-studies>.
- 10 16. Daly C, Welton JN, Dias S, Anwer S, Ades AE. Meta-Analysis of Continuous
11 Outcomes: Guideline Methodology Document 2. 2021. Available from:
12 <https://www.bristol.ac.uk/media-library/sites/social-community->
13 [medicine/documents/mpes/gmd-2-continuous-jan2021.pdf](https://www.bristol.ac.uk/media-library/sites/social-community-medicine/documents/mpes/gmd-2-continuous-jan2021.pdf)
- 14 17. Dohl O, Halsteinli V, Askim T, Gunnes M, Ihle-Hansen H, Indredavik B et al. Factors
15 contributing to post-stroke health care utilization and costs, secondary results from
16 the life after stroke (LAST) study. *BMC Health Services Research*. 2020; 20(1):288
- 17 18. English C, Bernhardt J, Crotty M, Esterman A, Segal L, Hillier S. Circuit class therapy
18 or seven-day week therapy for increasing rehabilitation intensity of therapy after
19 stroke (CIRCIT): A randomized controlled trial. *International Journal of Stroke*. 2015;
20 10(4):594-602
- 21 19. Fattore G, Torbica A, Susi A, Giovanni A, Benelli G, Gozzo M et al. The social and
22 economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-
23 centre cost of illness study. *BMC Neurology*. 2012; 12:137
- 24 20. Fernandez-Garcia C, Ternent L, Homer TM, Rodgers H, Bosomworth H, Shaw L et
25 al. Economic evaluation of robot-assisted training versus an enhanced upper limb
26 therapy programme or usual care for patients with moderate or severe upper limb
27 functional limitation due to stroke: results from the RATULS randomised controlled
28 trial. *BMJ Open*. 11(5):e042081
- 29 21. Forster A, Young J, Chapman K, Nixon J, Patel A, Holloway I et al. Cluster
30 Randomized Controlled Trial: Clinical and Cost-Effectiveness of a System of Longer-
31 Term Stroke Care. *Stroke*. 2015; 46(8):2212-2219
- 32 22. Ganesh A, Luengo-Fernandez R, Rothwell PM. Late functional improvement and 5-
33 year poststroke outcomes: A population-based cohort study. *Journal of Neurology,*
34 *Neurosurgery and Psychiatry*. 2020; 91(8):831-839
- 35 23. Glasgow Augmented Physiotherapy Study g. Can augmented physiotherapy input
36 enhance recovery of mobility after stroke? A randomized controlled trial. *Clinical*
37 *Rehabilitation*. 2004; 18(5):529-537
- 38 24. Han C, Wang Q, Meng PP, Qi MZ. Effects of intensity of arm training on hemiplegic
39 upper extremity motor recovery in stroke patients: a randomized controlled trial.
40 *Clinical Rehabilitation*. 2013; 27(1):75-81
- 41 25. Healthcare Quality Improvement Partnership. 2020/21 Sentinel Stoke National Audit
42 Programme (SSNAP) Annual Report 2021. Available from:

- 1 <https://www.hqip.org.uk/resource/sentinel-stroke-national-audit-programme-annual-report-2020-21/#.Yw3FzHbMKUI>
2
- 3 26. Hernández Alava M, Pudney S, Wailoo A. Estimating EQ-5D by age and sex for the
4 UK. 2022. Available from: [https://www.sheffield.ac.uk/nice-dsu/methods-](https://www.sheffield.ac.uk/nice-dsu/methods-development/estimating-eq-5d)
5 [development/estimating-eq-5d](https://www.sheffield.ac.uk/nice-dsu/methods-development/estimating-eq-5d)
- 6 27. Hernández Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-
7 5D-5L and EQ-5D-3L: results from an English population study Policy Research Unit
8 in Economic Evaluation of Health and Care Interventions. Universities of Sheffield
9 and York. 2020.
- 10 28. Howe TE, Taylor I, Finn P, Jones H. Lateral weight transference exercises following
11 acute stroke: a preliminary study of clinical effectiveness. *Clinical Rehabilitation*.
12 2005; 19(1):45-53
- 13 29. Hunt D, Smith JA. The personal experience of carers of stroke survivors: an
14 interpretative phenomenological analysis. *Disability and Rehabilitation*. 2004;
15 26(16):1000-1011
- 16 30. Hunter RM, Davie C, Rudd A, Thompson A, Walker H, Thomson N et al. Impact on
17 clinical and cost outcomes of a centralized approach to acute stroke care in London:
18 a comparative effectiveness before and after model. *PLoS One*. 2013; 8(8):e70420
- 19 31. Jiang S, You H, Zhao W, Zhang M. Effects of short-term upper limb robot-assisted
20 therapy on the rehabilitation of sub-acute stroke patients. *Technology and Health*
21 *Care*. 2020;
- 22 32. Jones K, Burns A. Unit costs of health and social care 2021. Canterbury. Personal
23 Social Services Research Unit University of Kent, 2021. Available from:
24 [https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-of-health-and-social-care-](https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-of-health-and-social-care-2021/)
25 [2021/](https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-of-health-and-social-care-2021/)
- 26 33. Kim SM, Han EY, Kim BR, Hyun CW. Clinical application of circuit training for
27 subacute stroke patients: a preliminary study. *Journal of Physical Therapy Science*.
28 2016; 28(1):169-174
- 29 34. Klassen TD, Dukelow SP, Bayley MT, Benavente O, Hill MD, Krassioukov A et al.
30 Higher Doses Improve Walking Recovery During Stroke Inpatient Rehabilitation.
31 *Stroke*. 2020; 51(9):2639-2648
- 32 35. Latimer NR, Bhadhuri A, Alshreef A, Palmer R, Cross E, Dimairo M et al. Self-
33 managed, computerised word finding therapy as an add-on to usual care for chronic
34 aphasia post-stroke: An economic evaluation. *Clinical Rehabilitation*. 2021;
35 35(5):703-717
- 36 36. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of
37 cardiovascular diseases in the enlarged European Union. *European Heart Journal*.
38 2006; 27(13):1610-1619
- 39 37. Lee SH, Byun SD, Kim CH, Go JY, Nam HU, Huh JS. Feasibility and Effects of Newly
40 Developed Balance Control Trainer for Mobility and Balance in Chronic Stroke
41 Patients: a Randomized Controlled Trial. *Annals of rehabilitation medicine*. 2012;
42 36(4):521-529

- 1 38. Leno Diaz C, Holguin Mohedas M, Hidalgo Jimenez N, Rodriguez-Ramos M, Lavado
2 Garcia JM. Long-term health-related quality of life in stroke survivors. *Revista*
3 *Cientifica de la Sociedad Espanola de Enfermeria Neurologica*. 2016; 44:9-15
- 4 39. Luengo-Fernandez R, Yiin GS, Gray AM, Rothwell PM. Population-based study of
5 acute- and long-term care costs after stroke in patients with AF. *International Journal*
6 *of Stroke*. 2013; 8(5):308-314
- 7 40. National Institute for H, Care E. Stroke rehabilitation in adults, NICE Guideline 162.
8 2013. Available from: <https://www.nice.org.uk/guidance/cg162>
- 9 41. National Institute for Health and Care Excellence. Developing NICE guidelines: the
10 manual [updated January 2022]. London. National Institute for Health and Care
11 Excellence, 2014. Available from: <https://www.nice.org.uk/process/pmg20>
- 12 42. National Institute for Health and Care Excellence. The NICE Charter. 2020. Available
13 from: <https://www.nice.org.uk/about/who-we-are/our-charter> Last accessed:
14 24/03/2022.
- 15 43. National Institute for Health and Care Excellence. NICE DSU Technical Support
16 Document 10: The Use of Mapping Methods to Estimate Health State Utility Values.
17 2011. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK425834/>
- 18 44. National Institute for Health and Clinical Excellence. Guide to the methods of
19 technology appraisal 2013. London. National Institute for Health and Clinical
20 Excellence, 2013. Available from: <http://publications.nice.org.uk/pmg9>
- 21 45. National Institute for Health and Clinical Excellence. Our principles. London. National
22 Institute for Health and Clinical Excellence, 2020. Available from:
23 <https://www.nice.org.uk/about/who-we-are/our-principles#introduction>
- 24 46. Neter J, Wasserman W, Kutner MH. Applied Linear Regression Models. 1983.
25 Available from: [https://www.semanticscholar.org/paper/Applied-Linear-Regression-
26 Models-Neter-Wasserman/731df2bb791c3fa221ca9498bfe43bb04b698357](https://www.semanticscholar.org/paper/Applied-Linear-Regression-Models-Neter-Wasserman/731df2bb791c3fa221ca9498bfe43bb04b698357)
- 27 47. NHS England. National tariff workbook (Annex A) - updated for national insurance
28 changes. 2022/23. Available from: [https://www.england.nhs.uk/publication/national-
29 tariff-payment-system-documents-annexes-and-supporting-documents/](https://www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/)
- 30 48. NICE Decision Support Unit. Mapping EQ-5D-5L to 3L. 2019. Available from:
31 <https://www.sheffield.ac.uk/nice-dsu/methods-development/mapping-eq-5d-5l-3l>
- 32 49. O'Connor RJ, Beden R, Pilling A, Chamberlain MA. What reductions in dependency
33 costs result from treatment in an inpatient neurological rehabilitation unit for people
34 with stroke? *Clin Med (Lond)*. 2011; 11(1):40-43
- 35 50. Office for National Statistics. National life tables – England: 2017 to 2019. 2021.
36 Available from:
37 [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lif
38 eexpectancies/datasets/nationallifetablesenglandreferencetables](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesenglandreferencetables) Last accessed:
39 26/07/2022.
- 40 51. Peiris CL, Taylor NF, Watts JJ, Shields N, Brusco NK, Mortimer D. Mapping the
41 Functional Independence Measure to a multi-attribute utility instrument for economic

- 1 evaluations in rehabilitation: a secondary analysis of randomized controlled trial data.
2 Disability and Rehabilitation. 2020; 42(21):3024-3032
- 3 52. Pennington B, Wong R. Modelling carer health-related quality of life in nice
4 technology appraisals and highly specialised technologies. Sheffield. Decision
5 Support Unit SchARR University of Sheffield, 2019. Available from:
6 [https://www.sheffield.ac.uk/nice-dsu/methods-development/carer-health-related-](https://www.sheffield.ac.uk/nice-dsu/methods-development/carer-health-related-quality-life)
7 [quality-life](https://www.sheffield.ac.uk/nice-dsu/methods-development/carer-health-related-quality-life)
- 8 53. Persson J, Levin, Holmegaard L, Redfors P, Jood K, Jern C et al. Stroke survivors'
9 long-term QALY-weights in relation to their spouses' QALY-weights and informal
10 support: A cross-sectional study. Health and Quality of Life Outcomes. 2017; 15(1)
- 11 54. Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez
12 R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol
13 (EQ-5D) health outcome. Medical Decision Making. 2010; 30(3):341-354
- 14 55. Rodgers H, Bosomworth H, Krebs HI, van Wijck F, Howel D, Wilson N et al. Robot
15 assisted training for the upper limb after stroke (RATULS): a multicentre randomised
16 controlled trial. Lancet. 2019; 394(10192):51-62
- 17 56. Scope A, Bhadhuri A, Pennington B, Wong R. Systematic review of cost-utility
18 analyses that have included carer and family member healthrelated quality of life.
19 Sheffield. Decision Support Unit SchARR University of Sheffield, 2020. Available
20 from: [https://www.sheffield.ac.uk/nice-dsu/methods-development/carer-health-](https://www.sheffield.ac.uk/nice-dsu/methods-development/carer-health-related-quality-life)
21 [related-quality-life](https://www.sheffield.ac.uk/nice-dsu/methods-development/carer-health-related-quality-life)
- 22 57. SSNAP - Sentinel Stroke National Audit Programme. National Results. 2022.
23 Available from: [https://www.strokeaudit.org/results/Clinical-audit/National-](https://www.strokeaudit.org/results/Clinical-audit/National-Results.aspx)
24 [Results.aspx](https://www.strokeaudit.org/results/Clinical-audit/National-Results.aspx) Last accessed: 25/08/2022.
- 25 58. Stroke Association. Stroke statistics. Available from: [https://www.stroke.org.uk/what-](https://www.stroke.org.uk/what-is-stroke/stroke-statistics)
26 [is-stroke/stroke-statistics](https://www.stroke.org.uk/what-is-stroke/stroke-statistics) Last accessed: 02/02/2023.
- 27 59. Tollar J, Nagy F, Csutoras B, Prontvai N, Nagy Z, Torok K et al. High Frequency and
28 Intensity Rehabilitation in 641 Subacute Ischemic Stroke Patients. Archives of
29 Physical Medicine and Rehabilitation. 2021; 102(1):9-18
- 30 60. Turner-Stokes L, Tonge P, Nyein K, Hunter M, Nielson S, Robinson I. The Northwick
31 Park Dependency Score (NPDS): a measure of nursing dependency in rehabilitation.
32 Clinical Rehabilitation. 1998; 12(4):304-318
- 33 61. van Exel NJ, Scholte op Reimer WJ, Koopmanschap MA. Assessment of post-stroke
34 quality of life in cost-effectiveness studies: the usefulness of the Barthel Index and the
35 EuroQoL-5D. Quality of Life Research. 2004; 13(2):427-433
- 36 62. Vloothuis JDM, Mulder M, Nijland RHM, Goedhart QS, Konijnenbelt M, Mulder H et
37 al. Caregiver-mediated exercises with e-health support for early supported discharge
38 after stroke (CARE4STROKE): A randomized controlled trial. PLoS ONE [Electronic
39 Resource]. 2019; 14(4):e0214241
- 40 63. Whynes DK, Sprigg N, Selby J, Berge E, Bath PM. Testing for differential item
41 functioning within the EQ-5D. Medical Decision Making. 2013; 33(2):252-260

- 1 64. Wilson A, Bath PM, Berge E, Cadilhac DA, Cuche M, Ford GA et al. Understanding
2 the relationship between costs and the modified Rankin Scale: A systematic review,
3 multidisciplinary consensus and recommendations for future studies. *European*
4 *Stroke Journal*. 2017; 2(1):3-12
- 5 65. Yoo D, Cha Y, Kim S, Lee J. Effect of three-dimensional robot-assisted therapy on
6 upper limb function of patients with stroke. *Journal of Physical Therapy Science*.
7 2013; 25(4):407-409.
- 8
- 9
- 10

1 Appendices

2 Appendix A: Search strategy

3 A.1 Health Economics literature search strategy

4 Health economic evidence was identified by conducting searches using terms for a broad
5 Stroke Rehabilitation population. The following databases were searched: NHS Economic
6 Evaluation Database (NHS EED - this ceased to be updated after 31st March 2015), Health
7 Technology Assessment database (HTA - this ceased to be updated from 31st March 2018)
8 and The International Network of Agencies for Health Technology Assessment (INAHTA).
9 Searches for recent evidence were run on Medline and Embase from 2014 onwards for
10 health economics, and all years for quality-of-life studies. Additional searches were run in
11 CINAHL and PsycInfo looking for health economic evidence.

12 **Table 2: Database parameters, filters and limits applied**

Database	Dates searched	Search filters and limits applied
Medline (OVID)	Health Economics 1 January 2014 – 08 January 2023	Health economics studies Quality of life studies
	Quality of Life 1946 – 08 January 2023	Exclusions (animal studies, letters, comments, editorials, case studies/reports,) English language
Embase (OVID)	Health Economics 1 January 2014 – 08 January 2023	Health economics studies Quality of life studies
	Quality of Life 1974 – 08 January 2023	Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts) English language
NHS Economic Evaluation Database (NHS EED) (Centre for Research and Dissemination - CRD)	Inception – 31 st March 2015	
Health Technology Assessment Database (HTA) (Centre for Research and Dissemination – CRD)	Inception – 31 st March 2018	
The International Network of Agencies for Health	Inception - 08 January 2023	English language

Database	Dates searched	Search filters and limits applied
Technology Assessment (INAHTA)		
Current Nursing and Allied Health Literature - CINAHL (EBSCO)	1 January 2014 – 08 January 2023	Health economics studies Exclusions (Medline records, animal studies, letters, editorials, comments, theses) Human English language
PsycINFO (OVID)	1 January 2014 – 08 January 2023	Health economics studies Exclusions (animal studies, letters, case reports) Human English language

1 Medline (Ovid) search terms

1.	exp Stroke/
2.	exp Cerebral Hemorrhage/
3.	(stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident").ti,ab.
4.	((cerebro* or brain or brainstem or cerebral*) adj3 (infarct* or accident*)).ti,ab.
5.	"brain attack*".ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/

20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice or rodent*).ti.
24.	or/17-23
25.	6 not 24
26.	Economics/
27.	Value of life/
28.	exp "Costs and Cost Analysis"/
29.	exp Economics, Hospital/
30.	exp Economics, Medical/
31.	Economics, Nursing/
32.	Economics, Pharmaceutical/
33.	exp "Fees and Charges"/
34.	exp Budgets/
35.	budget*.ti,ab.
36.	cost*.ti.
37.	(economic* or pharmaco?economic*).ti.
38.	(price* or pricing*).ti,ab.
39.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
40.	(financ* or fee or fees).ti,ab.
41.	(value adj2 (money or monetary)).ti,ab.
42.	or/26-41
43.	quality-adjusted life years/
44.	sickness impact profile/
45.	(quality adj2 (wellbeing or well being)).ti,ab.
46.	sickness impact profile.ti,ab.
47.	disability adjusted life.ti,ab.
48.	(qal* or qtime* or qwb* or daly*).ti,ab.
49.	(euroqol* or eq5d* or eq 5*).ti,ab.
50.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
51.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
52.	(hui or hui1 or hui2 or hui3).ti,ab.
53.	(health* year* equivalent* or hye or hyes).ti,ab.
54.	discrete choice*.ti,ab.
55.	rosser.ti,ab.

56.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
57.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
58.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
59.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
60.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
61.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
62.	or/43-61
63.	25 and 42
64.	25 and 62
65.	limit 63 to English language
66.	limit 64 to English language

1 Embase (Ovid) search terms

1.	exp Cerebrovascular accident/
2.	exp Brain infarction/
3.	(stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident").ti,ab.
4.	((cerebro* or brain or brainstem or cerebral*) adj3 (infarct* or accident*).ti,ab.
5.	"brain attack".ti,ab.
6.	Intracerebral hemorrhage/
7.	or/1-6
8.	letter.pt. or letter/
9.	note.pt.
10.	editorial.pt.
11.	case report/ or case study/
12.	(letter or comment*).ti.
13.	or/8-12
14.	randomized controlled trial/ or random*.ti,ab.
15.	13 not 14
16.	animal/ not human/
17.	nonhuman/
18.	exp Animal Experiment/
19.	exp Experimental Animal/
20.	animal model/
21.	exp Rodent/
22.	(rat or rats or mouse or mice).ti.
23.	or/15-22
24.	7 not 23
25.	health economics/

26.	exp economic evaluation/
27.	exp health care cost/
28.	exp fee/
29.	budget/
30.	funding/
31.	budget*.ti,ab.
32.	cost*.ti.
33.	(economic* or pharmaco?economic*).ti.
34.	(price* or pricing*).ti,ab.
35.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
36.	(financ* or fee or fees).ti,ab.
37.	(value adj2 (money or monetary)).ti,ab.
38.	or/25-37
39.	quality adjusted life year/
40.	"quality of life index"/
41.	short form 12/ or short form 20/ or short form 36/ or short form 8/
42.	sickness impact profile/
43.	(quality adj2 (wellbeing or well being)).ti,ab.
44.	sickness impact profile.ti,ab.
45.	disability adjusted life.ti,ab.
46.	(qal* or qtime* or qwb* or daly*).ti,ab.
47.	(euroqol* or eq5d* or eq 5*).ti,ab.
48.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
49.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
50.	(hui or hui1 or hui2 or hui3).ti,ab.
51.	(health* year* equivalent* or hye or hyes).ti,ab.
52.	discrete choice*.ti,ab.
53.	rosser.ti,ab.
54.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
55.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
56.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
57.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
58.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
59.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
60.	or/39-59
61.	limit 24 to English language
62.	38 and 61
63.	60 and 61

1 **NHS EED and HTA (CRD) search terms**

#1.	MeSH DESCRIPTOR Stroke EXPLODE ALL TREES
#2.	MeSH DESCRIPTOR Cerebral Hemorrhage EXPLODE ALL TREES
#3.	(stroke* or cva or poststroke* or apoplexy or "cerebrovascular accident")
#4.	((cerebro* or brain or brainstem or cerebral*) adj3 (infarct* or accident*))
#5.	("brain attack**")
#6.	#1 OR #2 OR #3 OR #4 OR #5

2 **INAHTA search terms**

1.	(brain attack*) OR (((cerebro* or brain or brainstem or cerebral*) and (infarct* or accident*)) OR ((stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident")) OR ("Cerebral Hemorrhage"[mhe]) OR ("Stroke"[mhe])
----	---

3 **CINAHL search terms**

1.	MH "Economics+"
2.	MH "Financial Management+"
3.	MH "Financial Support+"
4.	MH "Financing, Organized+"
5.	MH "Business+"
6.	S2 OR S3 or S4 OR S5
7.	S1 not S6
8.	MH "Health Resource Allocation"
9.	MH "Health Resource Utilization"
10.	S8 OR S9
11.	S7 OR S10
12.	(cost or costs or economic* or pharmacoeconomic* or price* or pricing*) OR AB (cost or costs or economic* or pharmacoeconomic* or price* or pricing*)
13.	S11 OR S12
14.	PT editorial
15.	PT letter
16.	PT commentary
17.	S14 or S15 or S16
18.	S13 NOT S17
19.	MH "Animal Studies"
20.	(ZT "doctoral dissertation") or (ZT "masters thesis")
21.	S18 NOT (S19 OR S20)
22.	PY 2014-
23.	S21 AND S22
24.	MW Stroke or MH Cerebral Hemorrhage
25.	stroke* or cva or poststroke* or apoplexy or "cerebrovascular accident"
26.	(cerebro* OR brain OR brainstem OR cerebral*) AND (infarct* OR accident*)
27.	"brain attack**"

28.	S24 OR S25 OR S26 OR S27
29.	S23 AND S28

1 **PsycINFO search terms**

1.	exp Stroke/
2.	exp Cerebral hemorrhage/
3.	(stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident").ti,ab.
4.	((cerebro* or brain or brainstem or cerebral*) adj3 (infarct* or accident*)).ti,ab.
5.	"brain attack".ti,ab.
6.	Cerebrovascular accidents/
7.	exp Brain damage/
8.	(brain adj2 injur*).ti.
9.	or/1-8
10.	Letter/
11.	Case report/
12.	exp Rodents/
13.	or/10-12
14.	9 not 13
15.	limit 14 to (human and English language)
16.	First posting.ps.
17.	15 and 16
18.	15 or 17
19.	"costs and cost analysis"/
20.	"Cost Containment"/
21.	(economic adj2 evaluation\$).ti,ab.
22.	(economic adj2 analy\$).ti,ab.
23.	(economic adj2 (study or studies)).ti,ab.
24.	(cost adj2 evaluation\$).ti,ab.
25.	(cost adj2 analy\$).ti,ab.
26.	(cost adj2 (study or studies)).ti,ab.
27.	(cost adj2 effective\$).ti,ab.
28.	(cost adj2 benefit\$).ti,ab.
29.	(cost adj2 utili\$).ti,ab.
30.	(cost adj2 minimi\$).ti,ab.
31.	(cost adj2 consequence\$).ti,ab.
32.	(cost adj2 comparison\$).ti,ab.
33.	(cost adj2 identificat\$).ti,ab.
34.	(pharmacoeconomic\$ or pharmaco-economic\$).ti,ab.

35.	or/19-34
36.	(0003-4819 or 0003-9926 or 0959-8146 or 0098-7484 or 0140-6736 or 0028-4793 or 1469-493X).is.
37.	35 not 36
38.	18 and 37

1

Appendix B: Clinical outcomes by study

Study	Timepoints	Mean	N	SD	SE	LCI	UCI	EQ-5D-3L mapped values				
								Mean	LCI	UCI	SD	SE
Cabanas-Valdes 2016 BI (0-100)	Lower intensity											
	Baseline	30.9	40	15.080	2.384	26.077	35.723	0.059	0.011	0.107	0.156	0.025
	CFBL	23.3	39	16.870	2.701			0.233			0.212	
	5 weeks	54.2	39	23.320	3.734	46.671	61.789	0.292	0.217	0.368	0.241	0.039
	Higher intensity											
	Baseline	32.0	40	15.270	2.414	27.116	36.884	0.070	0.021	0.119	0.158	0.025
	CFBL	36.5	40	18.810	2.974			0.365			0.204	
5 weeks	68.5	40	22.370	3.537	61.346	75.654	0.435	0.363	0.507	0.231	0.037	
Han 2013 BI (0-100)	Lower intensity											
	Baseline	51.5	10	22.490	7.112	35.412	67.588	0.265	0.104	0.426	0.260	0.082
	CFBL	33.5	10	19.485	6.162			0.335			0.225	
	6 weeks	85	10	11.790	3.728	76.566	93.434	0.600	0.516	0.684	0.136	0.043
	Higher intensity											
	Baseline	62.5	10	22.490	7.112	46.412	78.588	0.375	0.214	0.536	0.260	0.082
	CFBL	25.5	10	19.485	6.162			0.255			0.225	
6 weeks	88	10	11.790	3.728	79.566	96.434	0.630	0.546	0.714	0.136	0.043	
Jiang 2020 BI (0-100)	Lower intensity											
	Baseline	60	22	11.340	2.418	54.972	65.028	0.350	0.300	0.400	0.120	0.026

Stroke rehabilitation: DRAFT FOR CONSULTATION

Cost-utility analysis: intensity of physiotherapy rehabilitation

	CFBL	0.5	22	11.652	2.484			0.004			0.124		
	2 weeks	60.45	22	11.940	2.546	55.156	65.744	0.355	0.302	0.407	0.127	0.027	
	CFBL	2.5	22	11.755	2.506			0.025			0.125		
	1 month	62.5	22	12.130	2.586	57.122	67.878	0.375	0.321	0.429	0.129	0.027	
	Higher intensity												
	Baseline	66.74	23	13.020	2.715	61.110	72.370	0.417	0.361	0.474	0.138	0.029	
	CFBL	3.7	23	13.167	2.746			0.037			0.139		
	2 weeks	70.43	23	13.310	2.775	64.674	76.186	0.454	0.397	0.512	0.141	0.029	
	CFBL	5.4	23	13.251	2.763			0.054			0.140		
	4 weeks	72.17	23	13.470	2.809	66.345	77.995	0.472	0.413	0.530	0.143	0.030	
Kim 2016 BI (0-100)	Lower intensity												
	Baseline	57.4	10	22.400	7.084	41.376	73.424	0.324	0.164	0.484	0.259	0.082	
	CFBL	27.9	10	14.930	4.721			0.279			0.226		
	4 weeks	85.3	10	13.700	4.332	75.500	95.100	0.603	0.505	0.701	0.158	0.050	
	Higher intensity												
	Baseline	65.7	10	23.300	7.368	49.032	82.368	0.407	0.240	0.574	0.269	0.085	
CFBL	21.3	10	15.130	4.785			0.213			0.233			
4 weeks	87.0	10	10.500	3.320	79.489	94.511	0.620	0.545	0.695	0.121	0.038		
Klassen 2020 EQ-5D-5L	Lower intensity												
	Baseline	0.60	49	0.183	0.026	0.548	0.653	0.465	0.346	0.525	0.321	0.046	
	CFBL1	0.15	49	0.162	0.023			0.197			0.284		
	1 month	0.75	49	0.126	0.018	0.715	0.787	0.662	0.633	0.688	0.100	0.014	
	CFBL2	0.20	37	0.160	0.026			0.235			0.289		
	6 months	0.80	37	0.111	0.018	0.766	0.840	0.700	0.673	0.726	0.082	0.014	
	CFBL3	0.18	37	0.167	0.027			0.221			0.283		
	12 months	0.78	37	0.143	0.023	0.737	0.832	0.686	0.651	0.720	0.108	0.018	

Stroke rehabilitation: DRAFT FOR CONSULTATION

Cost-utility analysis: intensity of physiotherapy rehabilitation

	Higher intensity											
	Baseline	0.65	25	0.190	0.038	0.570	0.730	0.521	0.361	0.645	0.361	0.072
	CFBL1	0.17	24	0.165	0.034			0.190			0.334	
	1 month	0.82	24	0.090	0.018	0.780	0.850	0.711	0.683	0.734	0.064	0.013
	CFBL2	0.12	23	0.177	0.037			0.154			0.313	
	6 months	0.77	23	0.160	0.033	0.700	0.840	0.676	0.575	0.726	0.185	0.039
	CFBL3	0.18	21	0.165	0.036			0.197			0.333	
	12 months	0.83	21	0.080	0.017	0.800	0.870	0.718	0.698	0.754	0.066	0.014
Lee 2012 BI (0-100)	Lower intensity											
	Baseline	65.6	20	13.500	3.019	59.282	71.918	0.406	0.343	0.469	0.144	0.032
	CFBL	1.7	20	13.401	2.997			0.017			0.143	
	2 weeks	67.3	20	13.300	2.974	61.075	73.525	0.423	0.361	0.485	0.142	0.032
	CFBL	2.5	20	13.073	2.923			0.025			0.140	
	4 weeks	68.1	20	12.600	2.817	62.203	73.997	0.431	0.372	0.490	0.135	0.030
	Higher intensity											
	Baseline	64	20	17.000	3.801	56.044	71.956	0.390	0.310	0.470	0.182	0.041
	CFBL	4.3	20	17.255	3.858			0.043			0.449	
	2 weeks	68.3	20	17.500	3.913	60.110	104.928	0.433	0.351	0.799	0.511	0.114
CFBL	6.4	20	17.521	3.918			0.064			0.187		
4 weeks	70.4	20	18.000	4.025	61.976	78.824	0.454	0.370	0.538	0.192	0.043	
Rodgers 2019 EQ-5D-5L	Lower intensity											
	Baseline	0.37	254	0.260	0.016	0.338	0.402	0.216	0.193	0.239	0.190	0.012
	CFBL	0.05	207	0.276	0.019			0.036			0.202	
	3 months	0.42	207	0.290	0.020	0.380	0.460	0.252	0.223	0.281	0.212	0.015
	CFBL	0.09	190	0.265	0.019			0.065			0.194	
	6 months	0.46	190	0.270	0.020	0.421	0.499	0.281	0.253	0.310	0.198	0.014

Stroke rehabilitation: DRAFT FOR CONSULTATION

Cost-utility analysis: intensity of physiotherapy rehabilitation

	Higher intensity											
	Baseline	0.38	513	0.255	0.011	0.353	0.397	0.220	0.204	0.236	0.186	0.008
	CFBL	0.09	468	0.255	0.012			0.065			0.186	
	3 months	0.47	468	0.255	0.012	0.442	0.488	0.285	0.268	0.302	0.187	0.009
	CFBL	0.10	445	0.269	0.013			0.076			0.196	
	6 months	0.48	445	0.281	0.013	0.454	0.506	0.296	0.277	0.315	0.206	0.010
Tollar 2021 BI (0-100)	Lower Intensity											
	Baseline	56	390	8.500	0.430	55.154	56.846	0.310	0.302	0.318	0.085	0.004
	CFBL	17.1	355	12.100	0.642			0.171			0.108	
	5 weeks	73.1	355	10.572	0.561	71.837	74.363	0.481	0.468	0.494	0.121	0.006
	Higher intensity											
	Baseline	56.2	290	20.980	1.232	53.775	58.625	0.312	0.288	0.336	0.211	0.012
CFBL	27.2	286	8.920	0.527			0.272			0.183		
5 weeks	83.4	286	8.958	0.530	82.362	84.438	0.584	0.574	0.594	0.090	0.005	
Alternative clinical studies												
Askim 2010	Lower intensity											
	Baseline	70.8	32	16.200	2.864	64.959	76.641	0.458	0.400	0.516	0.169	0.030
	CFBL1	15.5	32	16.378	2.895			0.155			0.170	
	4 weeks	86.3	32	16.550	2.926	80.333	92.267	0.613	0.553	0.673	0.172	0.030
	CFBL2	20.2	32	16.378	2.895			0.202			0.172	
	3 months	91	32	16.550	2.926	85.033	96.967	0.660	0.6003	0.7197	0.172	0.030
	CFBL3	20.6	32	16.561	2.928			0.206			0.174	
	26 weeks	91.4	32	16.900	2.988	85.307	97.493	0.664	0.603	0.725	0.176	0.031
	Higher intensity											
	Baseline	72.7	30	20.000	3.651	65.232	80.168	0.477	0.402	0.552	0.209	0.038
	CFBL1	15.3	30	17.987	3.284			0.153			0.188	
	4 weeks	88.0	30	14.850	2.711	82.455	93.545	0.630	0.575	0.685	0.155	0.028
CFBL2	19.3	30	17.987	3.284			0.193			0.155		
3 months	92	30	14.850	2.711	86.455	97.545	0.670	0.615	0.725	0.155	0.028	

Stroke rehabilitation: DRAFT FOR CONSULTATION

Cost-utility analysis: intensity of physiotherapy rehabilitation

	CFBL3	19.8	32	17.323	3.062			0.198			0.136	
	26 weeks	92.5	32	9.700	1.715	89.003	95.997	0.675	0.640	0.710	0.098	0.018
Cooke 2010 EQ-5D-5L	Lower intensity											
	Baseline	0.39	37	0.330	0.054	0.280	0.500	0.234	0.152	0.315	0.253	0.042
	CFBL1	0.08	32	0.320	0.057			0.059			0.246	
	6 weeks	0.47	32	0.310	0.055	0.358	0.582	0.293	0.210	0.376	0.238	0.042
	CFBL2	0.21	23	0.312	0.065			0.155			0.375	
	12 weeks	0.60	23	0.290	0.060	0.475	0.725	0.389	0.296	0.648	0.430	0.090
	Higher intensity											
	Baseline	0.39	68	0.372	0.045	0.300	0.480	0.234	0.168	0.301	0.280	0.034
	CFBL1	0.18	70	0.345	0.041			0.131			0.389	
	6 weeks	0.57	70	0.310	0.037	0.493	0.641	0.365	0.310	0.518	0.444	0.053
CFBL2	0.21	54	0.336	0.046			0.237			0.371		
12 weeks	0.6	54	0.280	0.038	0.523	0.677	0.472	0.333	0.557	0.421	0.057	
Glasgow 2004 BI (0-20)	Lower intensity											
	Baseline	10.3	35	3.100	0.524	9.235	11.365	0.265	0.212	0.318	0.161	0.027
	CFBL1	3.8	34	3.439	0.590			0.190			0.178	
	4 weeks	14.1	34	3.700	0.635	12.809	15.391	0.455	0.390	0.520	0.192	0.033
	CFBL2	5.8	33	3.205	0.558			0.290			0.183	
	3 months	16.1	33	3.300	0.574	14.930	17.270	0.555	0.496	0.614	0.171	0.030
	CFBL3	5.9	34	4.100	0.703			0.295			0.204	
	6 months	16.2	34	4.200	0.720	14.735	17.665	0.560	0.487	0.633	0.215	0.037
	Higher intensity											
	Baseline	11.8	35	3.3	0.56	10.666	12.934	0.340	0.283	0.397	0.171	0.029
CFBL1	2.8	33	3.4	0.58			0.140			0.174		
4 weeks	14.6	33	3.4	0.59	13.394	15.806	0.480	0.420	0.540	0.177	0.031	
CFBL2	4.8	32	3.1	0.54			0.240			0.163		

Stroke rehabilitation: DRAFT FOR CONSULTATION

Cost-utility analysis: intensity of physiotherapy rehabilitation

	3 months	16.6	32	2.8	0.49	15.590	17.610	0.580	0.530	0.630	0.146	0.026
	CFBL3	5.1	31	3.7	0.66			0.255			0.162	
	6 months	16.9	31	2.7	0.48	15.910	17.890	0.595	0.545	0.645	0.143	0.025
Yoo 2013 BI (0-100)	Lower intensity											
	Baseline	75.3	11	5.0	1.51	71.94	78.66	0.503	0.469	0.537	0.057	0.017
	CFBL1	0.1	11	5.1	1.52			0.001			0.057	
	4 weeks	75.4	11	5.1	1.54	71.97	78.83	0.504	0.470	0.538	0.058	0.017
	Higher intensity											
	Baseline	77.5	11	9.6	2.89	71.05	83.95	0.525	0.461	0.589	0.109	0.033
	CFBL1	0.4	11	9.7	2.91			0.004			0.110	
4 weeks	77.9	11	9.7	2.92	71.38	84.42	0.529	0.464	0.594	0.110	0.033	

Abbreviations: BI= Barthel Index; CFBL= change from baseline; EQ-5D-3L/5L= Euroqol 5 dimensions – 3 level/5 level version; LCI/UCI= 95% confidence interval (lower/upper); SD = standard deviation; SE= standard error.

Appendix C: Meta-analysis of EQ-5D-3L

	EQ-5D-3L					Weighting		Other parameters			
	BL	CFBL-L	MD	Var	1/Var	BC	All	Age	% F	Weeks	BI (0-100)
Cabanas-Valdes 2016	0.065	0.233	0.132	0.0020	456.8	12.20%	8.40%	76	50%	5	13.2
Han 2013	0.320	0.335	-0.080	0.0100	98.9	4.10%	3.00%	53	22%	6	-8.0
Jiang 2020	0.384	0.004	0.032	0.0020	646.4	14.50%	9.90%	64	36%	2	3.2
Kim 2016	0.366	0.279	-0.066	0.0105	94.9	4.00%	2.90%	66	35%	4	-6.6
Klassen 2020	0.484	0.197	-0.007	0.0056	177.3	6.60%	4.70%	57	41%	4	-0.7
Lee 2012	0.398	0.025	0.039	0.0030	367.0	10.80%	7.50%	54	38%	4	3.9
Rodgers pooled	0.219	0.036	0.029	0.0003	3931.9	23.20%	15.00%	61	39%	12	2.2
Tollar 2021	0.311	0.171	0.101	0.0001	7395.4	24.60%	15.70%	67	45%	5	10.1
Base case studies	0.294	0.120	0.050			100%		63	41%	6	4.9
Askim 2010	0.467	0.155	-0.002	0.0021	483.4	0.00%	8.70%	77	53%	4	-0.2
Cooke 2010	0.234	0.059	0.071	0.0056	178.5	0.00%	4.80%	68	40%	6	7.2
Glasgow 2004	0.303	0.190	-0.050	0.0020	539.1	0.00%	9.10%	68	41%	4	-5.0
Yoo 2013	0.514	0.001	0.003	0.0014	717.4	0.00%	10.30%	50	41%	6	0.3
All studies	0.330	0.115	0.032				100%	64	42%	6	3.1

Abbreviations: %F=percentage female at baseline; Age=mean age at baseline; BC=base case; BI=Barthel Index – difference in change from baseline; BL=baseline; CFBL-L=change from baseline in lower intensity group; MD=mean difference in change from baseline; Var= variance of the mean difference; weeks=duration of intervention in weeks